Compounds > salicylic acid
Page last updated: 2024-10-17

salicylic acid and Alopecia Circumscripta

salicylic acid has been researched along with Alopecia Circumscripta in 295 studies

Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).

Research Excerpts

ExcerptRelevanceReference
"The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata."10.163 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988)
"Although intralesional triamcinolone acetonide (TA) is the most commonly prescribed treatment for localized alopecia areata (AA), the literature regarding the optimal concentration for attaining better efficacy with the most acceptable side effects is scarce."9.41Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. ( Bains, A; Bhardwaj, A; Budania, A; Kumar-M, P; Rajan M, B; Singh, S; Thirunavukkarasu, P, 2021)
"We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata."9.14Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. ( Bassett, R; Duvic, M; Stevens, V; Talpur, R; Vu, J, 2009)
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects."7.91Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019)
" A treatment trial with topical immunotherapy using diphenylcyclopropenone was unsuccessful, which might be explained by both long-standing alopecia areata and the underlying immune deficiency with an impaired delayed hypersensitivity reaction."7.69Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. ( Böni, R; Trüeb, RM; Wüthrich, B, 1995)
"Ninety patients with alopecia areata were treated with weekly applications to one side of the head of dinitrochlorobenzene (DNCB) dissolved in acetone, the other side of the head serving as control region."7.66Dinitrochlorobenzene therapy for alopecia areata. ( Cebulla, K; Echternacht-Happle, K; Happle, R, 1978)
"Anthralin 1% is an effective therapy for AA and should be continued at least 9 months."6.84Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017)
"The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata."6.163 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988)
"Although intralesional triamcinolone acetonide (TA) is the most commonly prescribed treatment for localized alopecia areata (AA), the literature regarding the optimal concentration for attaining better efficacy with the most acceptable side effects is scarce."5.41Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. ( Bains, A; Bhardwaj, A; Budania, A; Kumar-M, P; Rajan M, B; Singh, S; Thirunavukkarasu, P, 2021)
"Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface."5.36Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010)
"We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata."5.14Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. ( Bassett, R; Duvic, M; Stevens, V; Talpur, R; Vu, J, 2009)
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects."3.91Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019)
"In this retrospective, cross-sectional case series, 18 patients with patchy alopecia areata treated at 4- to 8-week intervals with intralesional triamcinolone acetonide for at least 20 months were evaluated for BMD using dual-energy x-ray absorptiometry (DXA)."3.79Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. ( Fu, JM; Harris, ST; Price, VH; Samrao, A, 2013)
"Localized hair shedding caused by Pheidole ants is reported as a newly recognized type of hair loss, mimicking alopecia areata."3.72Localized scalp hair shedding caused by Pheidole ants and overwiew of similar case reports. ( Shamsadini, S, 2003)
" A treatment trial with topical immunotherapy using diphenylcyclopropenone was unsuccessful, which might be explained by both long-standing alopecia areata and the underlying immune deficiency with an impaired delayed hypersensitivity reaction."3.69Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. ( Böni, R; Trüeb, RM; Wüthrich, B, 1995)
"Ninety patients with alopecia areata were treated with weekly applications to one side of the head of dinitrochlorobenzene (DNCB) dissolved in acetone, the other side of the head serving as control region."3.66Dinitrochlorobenzene therapy for alopecia areata. ( Cebulla, K; Echternacht-Happle, K; Happle, R, 1978)
"Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the hair follicle level."3.01Alopecia Areata: Current Treatments and New Directions. ( Bar, J; Dahabreh, D; Del Duca, E; Guttman-Yassky, E; Jung, S; Renert-Yuval, Y, 2023)
" The adverse effects of ALA-PDT were mild, which indicated safety and tolerability of this treatment."3.01Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety. ( Cao, Z; Hu, W; Liu, X; Wang, P; Wang, X; Zhang, G; Zhang, L; Zhang, Y; Zhou, Z, 2021)
"Anthralin 1% is an effective therapy for AA and should be continued at least 9 months."2.84Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017)
"It can be severe and lead to complete hair loss of the scalp or the whole body."2.82[Janus kinase inhibitors for the treatment of alopecia areata]. ( Kobal, I; Ramot, Y, 2022)
"The most important hair diseases are divided in non- cicatricial and cicatricial ones."2.72Common causes of hair loss - clinical manifestations, trichoscopy and therapy. ( Alessandrini, A; Bruni, F; Piraccini, BM; Starace, M, 2021)
"The rapid rate of hair loss and disfiguration caused by the condition causes anxiety on patients and increases the risks of developing psychological and psychiatric complications."2.61Alopecia areata: A multifactorial autoimmune condition. ( Butcher, JP; Henriquez, FL; Reid, S; Simakou, T, 2019)
"Cutaneous and systemic lupus erythematosus (SLE) commonly involves the hair and scalp."2.58Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus. ( Chanprapaph, K; Suchonwanit, P; Udompanich, S, 2018)
"Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle."2.55Alopecia areata. ( Christiano, AM; King, LE; Messenger, AG; Pratt, CH; Sundberg, JP, 2017)
"The non scarring form is a finding of acute systemic LE and the scarring form develops when a typical discoid lesion is located on the scalp."2.50Hair loss in autoimmune systemic diseases. ( Cozzani, E; Parodi, A, 2014)
"Alopecia areata is a chronic inflammatory non-scarring condition affecting the hair follicle that leads to hair loss ranging from small well defined patches to complete loss of all body hair."2.49Alopecia areata: more than skin deep. ( MacLean, KJ; Tidman, MJ, 2013)
"Based on these findings, a diagnosis of blue nevus, cellular type, was made."2.47Coexistence of giant blue nevus of the scalp with hair loss and alopecia areata. ( Ansai, S; Arase, S; Inoue, N; Kubo, Y; Murao, K; Takeichi, S, 2011)
"Localized scalp hair loss is associated with many processes, including alopecia areata, trichotillomania, tinea capitis, and early lupus erythematosus."2.42Ant-induced alopecia: report of 2 cases and review of the literature. ( Mansouri, P; Mortazavi, M, 2004)
"We present a case of cicatricial pemphigoid with significant scarring alopecia as a major manifestation and review our series of cicatricial pemphigoid patients in Oxford (UK)."2.40Cicatricial pemphigoid rarely involves the scalp. ( Ball, S; Walkden, V; Wojnarowska, F, 1998)
"Alopecia areata was mimicked very closely."2.40Scalp metastases mimicking alopecia areata. First case report of placental site trophoblastic tumor presenting as cutaneous metastasis. ( Larson, JT; Lewis, EJ; Rest, EB; Wilke, MS; Yuen, YF; Zachary, CB, 1998)
"A woman with no previous history of breast carcinoma presented with focal hair loss, which was presumptively diagnosed as alopecia areata."2.39Alopecia neoplastica simulating alopecia areata and antedating the detection of primary breast carcinoma. ( Carson, HJ; Lack, E; Pellettiere, EV, 1994)
"A generalizable automated assessment of hair loss would provide a way to standardize measurements of hair loss across a range of conditions."1.91Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores. ( Bayramova, A; Bernardis, E; Castelo-Soccio, L; Cotsarelis, G; Gudobba, C; Mane, T; Ogunleye, TA; Rodriguez, N; Taylor, SC, 2023)
"The most prevalent HSRDs included androgenetic alopecia (30."1.91Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre. ( Barzilai, A; Baum, S; Galili, E; Gilboa, S; Lyakhovitsky, A; Segal, O; Tzanani, I, 2023)
"Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body."1.91Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023)
"Granuloma annulare is a benign inflammatory illness with no known cause that might be difficult to cure."1.91Granuloma annulare with alopecia areata in a 6-year-old girl: a case report. ( Fatemeh, S; Moeine, R; Mohaghegh, F; Nekooeian, M; Saber, M; Shahriarirad, R, 2023)
"Telogen effluvium, androgenetic alopecia, and alopecia areata are the most common forms of nonscarring alopecias."1.72Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom? ( Akdeniz, N; Öner, Ü, 2022)
"Institutions conducting research on treatment for alopecia areata can use the results of this study to better understand the needs of their target population."1.72Characterizing the willingness to undergo treatment in patients with alopecia areata. ( O'Connor, LF; Wells, KM, 2022)
"Alopecia areata is a common non-scarring hair loss disorder."1.62Expression of survivin and p53 genes in patients with alopecia areata: A case-control study. ( Abd El-Fadeal, NM; Atef, LM; Marie, REM, 2021)
"Six patients had progression of their hair loss in spite of treatment."1.62Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study. ( Bhoyrul, B; Jerjen, R; Pinczewski, J; Sinclair, R, 2021)
"Scalp-hair loss was the most bothersome AA sign/symptom for most patients."1.56The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. ( Aldhouse, NVJ; Dutronc, Y; King, BA; Kitchen, H; Knight, S; Ko, JM; Macey, J; Mesinkovska, N; Nunes, FP; Wyrwich, KW, 2020)
"Alopecia areata (AA) is an autoimmune hair loss condition that is difficult to treat and frequently disruptive to the psychosocial well-being of patients."1.56Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series. ( Chen, Z; Choi, F; Csuka, E; Ekelem, C; Heidari, AE; Hosking, AM; Juhasz, M; Mesinkovska, NA; Pham, CT; Rapaport, JA; Valdebran, M; Yu, J, 2020)
"Alopecia areata affects not only scalp hair but also other sites of body hair, including eyebrows."1.56Eyebrows Are Important in the Treatment of Alopecia Areata. ( King, BA; Ko, JM; Liu, LY, 2020)
"All patients named scalp hair loss as a key AA sign or symptom."1.56Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. ( Aldhouse, NVJ; Dutronc, Y; King, BA; Kitchen, H; Knight, S; Ko, JM; Macey, J; Mesinkovska, N; Nunes, FP; Wyrwich, KW, 2020)
"Of note, patchy primary scarring alopecia (SA) needs to be clearly distinguished from AA as SA can leave permanent hair loss."1.51Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient. ( Fukuyama, M; Ohyama, M, 2019)
"Tinea capitis is a scalp infection caused by different fungi."1.48A prospective study of tinea capitis in children: making the diagnosis easier with a dermoscope. ( Aqil, N; BayBay, H; Douhi, Z; Elloudi, S; Mernissi, FZ; Moustaide, K, 2018)
"Resistance to the standard treatment for alopecia areata prompted a biopsy that proved the diagnosis."1.46Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. ( Hoverson, K; Jarell, AD; Wohltmann, WE, 2017)
" In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA."1.46Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years. ( Jun, M; Lee, NR; Lee, WS, 2017)
"Alopecia areata was commoner in men (M:F=1."1.40An observational study of alopecia areata in Sri Lankan adult patients. ( Ranawaka, RR, 2014)
"Alopecia areata is an autoimmune disease associated with other autoimmune diseases such as thyroid disorders, anemia, and other skin disorders."1.39Graves' disease associated with alopecia areata developing after Hashimoto's thyroiditis. ( Aşık, M; Binnetoğlu, E; Şen, H; Tekeli, Z; Ukinç, K; Uysal, F, 2013)
"Vitiligo is caused by the destruction of melanocytes and results in the appearance of white patches on any part of the body, while alopecia areata is characterized by patchy hair loss primarily on the scalp, but may also involve other areas as well."1.39Vitiligo and alopecia areata: apples and oranges? ( Harris, JE, 2013)
"The diagnosis of cerebriform intradermal nevus was confirmed."1.36Letter: Cerebriform intradermal nevus presenting as secondary cutis verticis gyrata. ( Alcántara González, J; Carrillo Gijón, R; Jaén Olasolo, P; Martín Diaz, RM; Truchuelo Díez, MT, 2010)
"Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface."1.36Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010)
"Alopecia areata is considered to be a T-cell mediated autoimmune disorder."1.36Treatment of alopecia areata with 308-nm excimer lamp. ( Hasegawa, T; Ikeda, S; Ohtsuki, A, 2010)
"Commonly occurring hair loss in children in our region is mainly acquired, and the clinical course is related to the parent's attitude to treatment, particularly for tinea capitis."1.34Hair loss in children in South-East Nigeria: common and uncommon cases. ( Maduechesi, C; Nnoruka, EN; Obiagboso, I, 2007)
"Alopecia areata is a common form of nonscarring hair disorder of unclear etiology."1.33Alopecia areata universalis sparing nevus flammeus. ( Chen, W, 2005)
"Scalp metastasis from breast carcinoma is reported but it is rare."1.33Multifocal scalp hair loss. ( Ebrahimi, H; Esfandiarpoor, I; Kalantari, B; Shamsadin, S; Zeinali, H, 2006)
"We describe a female patient with linear scleroderma en coup de sabre and a longstanding clinical history of tonic and clonic convulsions."1.32Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? ( Espinoza, LR; Esquivel-Valerio, JA; Flores-Alvarado, DE; Garza-Elizondo, M, 2003)
"Alopecia areata is an autoimmune condition directed at hair follicles, which results in loss of hair."1.32Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response. ( Assy, B; Gilhar, A; Kalish, RS; Landau, M; Serafimovich, S; Shalaginov, R; Ullmann, Y, 2003)
"Alopecia areata has been reported to be accompanied by abnormal autoimmune dysfunction."1.31Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. ( Nakamura, K; Okochi, H; Tamaki, K; Yano, S, 2002)
"Although alopecia areata is a common problem among children, many misdiagnoses for this condition can happen."1.31Striae distensae-like lesions. A cause of scarring alopecia among children. ( Al-Nuaimy, AA; Al-Waiz, MM; Sharquie, KE, 2002)
"We studied skin biopsies from 11 untreated alopecia areata patients and two normal controls."1.31Role of cytotoxic T cells in chronic alopecia areata. ( Bodemer, C; Brousse, N; Chatenoud, L; De Prost, Y; Fraitaig, S; Peuchmaur, M, 2000)
"Alopecia areata is a tissue restricted autoimmune condition affecting the hair follicle, resulting in hair loss."1.31Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. ( Assy, B; Gilhar, A; Kalish, RS; Landau, M; Serafimovich, S; Shalaginov, R, 2001)
"Alopecia areata is a tissue-restricted autoimmune disease of the hair follicle, which results in hair loss and baldness."1.30Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. ( Assy, B; Berkutzki, T; Gilhar, A; Kalish, RS; Ullmann, Y, 1998)
"Alopecia areata is a common cause of hair loss in children and adults."1.30Diagnosis: alopecia areata or not? ( Grant-Kels, JM; Hoss, DM, 1999)
"Gonosomal aberrations such as Turner's syndrome are frequently associated with autoimmune diseases or with serological markers for autoimmune diseases."1.29[Alopecia areata and diffuse hypotrichosis associated with Ullrich-Turner syndrome. Presentation of 4 patients]. ( Gollnick, H; Müller, R; Orfanos, CE; Reupke, HJ; Tebbe, B, 1993)
"Alopecia areata is a form of balding whose aetiology is uncertain."1.29Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps. ( Baker, TG; Cunliffe, WJ; MacDonald Hull, SP; Nutbrown, M; Randall, VA, 1996)
"Hair loss is a common problem likely to be encountered by a clinical practitioner."1.27Hair loss. Common congenital and acquired causes. ( Phillips, JH; Smith, SL; Storer, JS, 1986)
"While hair loss is usually of more psychologic than physiologic significance, accurate diagnosis can be of great importance."1.26Diagnosing the common alopecias. ( Ackerman, AB; Stengel, F, 1978)
"Sometimes male pattern baldness occurs in physiologic states, as exemplified by diffuse hair loss occasionally in the postpartum period."1.24Noncicatrizing alopecias; with special reference to alopecia areata. ( NEW, WN; NICKEL, WR, 1958)

Research

Studies (295)

TimeframeStudies, this research(%)All Research%
pre-199054 (18.31)18.7374
1990's45 (15.25)18.2507
2000's42 (14.24)29.6817
2010's82 (27.80)24.3611
2020's72 (24.41)2.80

Authors

AuthorsStudies
Uchida, Y2
Gherardini, J2
Pappelbaum, K1
Chéret, J1
Schulte-Mecklenbeck, A1
Gross, CC1
Strbo, N1
Gilhar, A5
Rossi, A2
Funk, W2
Kanekura, T1
Almeida, L1
Bertolini, M3
Paus, R7
O'Connor, LF1
Wells, KM1
Öner, Ü1
Akdeniz, N1
Di Mascio, D1
Sapino, G1
De Maria, F1
Macey, J5
Kitchen, H5
Aldhouse, NVJ5
Edson-Heredia, E1
Burge, R1
Prakash, A1
King, BA7
Mesinkovska, N4
Guttman-Yassky, E8
Pavel, AB6
Diaz, A1
Zhang, N4
Del Duca, E6
Estrada, Y2
King, B1
Banerjee, A1
Banfield, C1
Cox, LA1
Dowty, ME1
Page, K1
Vincent, MS1
Zhang, W1
Zhu, L1
Peeva, E1
Lintzeri, DA1
Constantinou, A1
Hillmann, K1
Ghoreschi, K1
Vogt, A2
Blume-Peytavi, U2
Rafati, M1
Mahmoudian, R1
Golpour, M1
Kazeminejad, A1
Saeedi, M1
Nekoukar, Z1
Kobal, I1
Ramot, Y2
Hawwam, SA1
Ismail, M1
Elhawary, EE1
Shakshouk, H1
Tosti, A9
Wyrwich, KW4
Knight, S4
Ko, JM6
Hu, D1
Yang, S2
Lyakhovitsky, A1
Tzanani, I1
Gilboa, S1
Segal, O1
Galili, E1
Baum, S1
Barzilai, A1
Sharma, A1
Vinay, K1
Chatterjee, D1
Narang, T2
Dogra, S2
Rinaldi, F4
Pinto, D4
Borsani, E1
Castrezzati, S1
Amedei, A1
Rezzani, R1
Renert-Yuval, Y4
Facheris, P1
Pagan, AD1
Bose, S1
Gómez-Arias, PJ1
Angelov, M2
Bares, J1
Chima, M1
Estrada, YD4
Garcet, S1
Lebwohl, MG1
Krueger, JG6
Abdel Hay, R2
Sayed, KS2
Mostafa, WZ2
Afifi, HA2
Gad, LZ2
El-Samanoudy, SI2
Gudobba, C2
Mane, T2
Bayramova, A2
Rodriguez, N2
Castelo-Soccio, L4
Ogunleye, TA3
Taylor, SC2
Cotsarelis, G2
Bernardis, E4
Saber, M2
Mardani, E1
Shahmoradi, Z1
Mohaghegh, F1
Moeine, R1
Fatemeh, S1
Nekooeian, M1
Shahriarirad, R1
Sode, T1
Ogwumike, E1
Hosler, GA1
Khalid, I1
Ober-Reynolds, B1
Wang, C1
Rios, EJ1
Aasi, SZ1
Davis, MM1
Oro, AE1
Greenleaf, WJ1
Ye, Y2
Wang, Y1
Zhu, J1
Huang, R1
Yu, Q1
Zhang, J1
Chen, X1
Wei, Z1
Han, Y1
Zhou, N1
Li, P2
Li, Y2
Dahabreh, D3
Jung, S1
Bar, J1
Phillipps, J1
Pollard, B1
Mann, C1
Kokubu, H1
Kataoka, K1
Kato, T1
Fujimoto, N1
Tachibana, T1
Kang, H1
Wu, WY1
Yu, M1
Shapiro, J4
McElwee, KJ2
Liu, ZH1
Xia, XJ1
Zhi, HL1
Zhong, Y1
Sang, B1
Lv, WW1
Li, QP1
Shen, H1
Kerkemeyer, KLS1
John, JM1
Sinclair, R2
Bhoyrul, B2
Starace, M2
Guicciardi, F1
Alessandrini, A2
Baraldi, C1
Ravaioli, GM1
Bruni, F2
Piraccini, BM4
Nunes, FP2
Dutronc, Y3
Cuellar-Barboza, A1
Cardenas-de la Garza, JA1
Cruz-Gómez, LG1
Barboza-Quintana, O1
Flores-Gutiérrez, JP1
Gómez-Flores, M1
Welsh, O1
Ocampo-Candiani, J1
Herz-Ruelas, ME1
Ruano Ruiz, J2
Sanyal, RD1
Song, T2
Gay-Mimbrera, J2
Peng, X1
Phelps, RG1
Blome, C1
Calabrese, FM1
De Angelis, M1
Celano, G1
Giuliani, G3
Gobbetti, M1
Gallo, R1
Trave, I1
Parodi, A2
Rencz, F1
Carvalho, RM1
Barreto, TM1
Weffort, F1
Machado, CJ1
Melo, DF1
Lee, S2
Lee, JW1
Choe, SJ3
Koh, SB1
Ahn, YS1
Lee, WS6
Shin, JM1
Kim, KH2
Kim, SM1
Hong, D1
Park, J2
Lee, HY1
Lim, WJ1
Shin, YA1
Kim, CD2
Seo, YJ2
Lee, JH2
Kim, N1
Lee, Y1
Hardman, JA1
Nicu, C1
Tai, C1
Harries, M1
Mironov, A1
Purba, TS1
Marie, REM1
Abd El-Fadeal, NM1
Atef, LM1
Trink, A1
Sorbellini, E2
Ito, T2
Yamamoto, T2
Martin, L1
Nicolas, JF1
Hegde, P1
Relhan, V1
Sahoo, B1
Garg, VK1
Seo, S1
Serarslan, G1
Özcan, O1
Okyay, E1
Ünlü, B1
Karadağ, M1
Liu, LY1
Ekelem, C1
Juhasz, M1
Yu, J1
Hosking, AM1
Csuka, E1
Choi, F1
Pham, CT1
Heidari, AE1
Valdebran, M1
Rapaport, JA1
Chen, Z1
Mesinkovska, NA3
Nunes, F1
Mofarrah, R2
Jahani Amiri, K1
Ghasemi, M1
Seyhan, T1
Kapi, E1
Rajan M, B1
Bhardwaj, A1
Singh, S1
Budania, A1
Bains, A1
Thirunavukkarasu, P1
Kumar-M, P1
Gong, Y1
Luo, L1
Li, L1
He, X1
Lu, W1
Sha, X1
Mao, Y1
Piccolo, D1
Crisman, G1
Conforti, C1
Buzzi, M1
Genovesi, C1
Marchi, D1
Mazzaracchio, D1
Goldust, M1
Genedy, RM1
Badran, FK1
Tayae, EM1
Sabra, HN1
Glickman, JW2
Dubin, C2
Han, J2
Kimmel, GW2
Singer, G2
Chennareddy, S1
Chowdhury, M1
Zheng, AY1
Majid, I1
Sameem, F1
Sultan, J1
Aleem, S1
Jerjen, R1
Pinczewski, J1
Cao, Z1
Liu, X1
Zhang, L1
Zhang, Y1
Zhou, Z1
Zhang, G1
Wang, P1
Hu, W1
Wang, X1
Hoverson, K1
Jarell, AD1
Wohltmann, WE1
Ibrahim, O1
Bayart, CB1
Hogan, S1
Piliang, M1
Bergfeld, WF3
Nukpezah, J1
Christensen, T1
Daroach, M1
Saikia, UN1
Sachdeva, N1
Sendhil Kumaran, M1
Loh, SH1
Moon, HN1
Lew, BL2
Sim, WY2
Melé-Ninot, G1
Expósito-Serrano, V1
Quintana Codina, M1
Iglesias Sancho, M1
Sánchez-Regaña, M1
Umbert Millet, P1
Salleras Redonnet, M1
Morsy, H1
Maher, R1
Negm, D1
Udompanich, S1
Chanprapaph, K1
Suchonwanit, P2
Wen, HC1
Malik, K1
Gonzalez, J1
Hashim, PW1
Nia, JK1
Baum, D1
Kimmel, G1
Singer, GK1
Yadav, D1
Khandpur, S1
Ramam, M1
Singh, MK1
Sharma, VK1
Lee, H2
de Jong, A1
Jabbari, A2
Dai, Z1
Xing, L1
Lee, D1
Li, MM1
Duvic, M2
Hordinsky, M1
Norris, DA1
Price, V1
Mackay-Wiggan, J1
Clynes, R1
Christiano, AM3
Zhang, X1
Zhu, Z1
Yang, Y1
Cao, H1
Ling, Y1
Elmaadawy, E1
Elgarhy, LH1
Shareef, M1
Simakou, T1
Butcher, JP1
Reid, S1
Henriquez, FL1
Aqil, N1
BayBay, H1
Moustaide, K1
Douhi, Z1
Elloudi, S1
Mernissi, FZ1
Wambier, CG1
Fukuyama, M1
Ohyama, M2
Marzani, B1
Rucco, M1
Polak-Witka, K1
Rudnicka, L4
Gautam, RK1
Singh, Y1
Gupta, A1
Arora, P1
Khurana, A1
Chitkara, A1
Petukhova, L1
Patel, AV1
Rigo, RK1
Bian, L1
Verbitsky, M1
Sanna-Cherchi, S1
Erjavec, SO1
Abdelaziz, AR1
Cerise, JE1
Khademi, F1
Tehranchinia, Z1
Abdollahimajd, F1
Younespour, S1
Kazemi-Bajestani, SMR1
Taheri, K1
Wang, W1
Christmann, R1
Thomas, C1
Jager, N1
Raber, AS1
Loretz, B1
Schaefer, UF1
Tschernig, T1
Vogt, T1
Lehr, CM1
Waśkiel-Burnat, A1
Rakowska, A2
Sikora, M1
Olszewska, M3
Giuffrida, R2
Borgia, F2
Marafioti, I1
Riso, G1
Cannavò, SP2
Patruno, C1
Napolitano, M1
Ferrillo, M1
Fabbrocini, G1
Paniz Mondolfi, AE1
Cressey, BD1
Ahmad, A1
Tapia-Centola, B1
Cohen, LM1
Mahmoodi, M1
Yamakoshi, T1
Andoh, T1
Makino, T2
Kuraishi, Y1
Shimizu, T1
Missall, TA1
Hurley, MY1
Burkemper, NM1
Ekiz, O1
Sen, BB1
Rifaioğlu, EN1
Balta, I1
Harris, JE1
Lamb, RC1
Porter, M1
Taş, B1
Pilanci, Ö1
Başaran, K1
MacLean, KJ1
Tidman, MJ1
Aşık, M1
Binnetoğlu, E1
Şen, H1
Tekeli, Z1
Uysal, F1
Ukinç, K1
Cozzani, E1
McMichael, A1
Olsen, EA1
Maly, A1
Zlotogorski, A1
Carvalho, VO1
Markus, JR1
Robl, R1
Uber, M1
Abagge, KT1
Marinoni, LP1
Mubki, T1
Sato, M1
Amagai, M1
Walker, A1
Boncher, J1
Tamburro, J1
Ranawaka, RR1
Zaher, H1
Gawdat, HI1
Hegazy, RA1
Hassan, M1
Angra, K1
LaSenna, CE1
Nichols, AJ1
Yazdani Abyaneh, MA1
Raghu, P1
Kircher, K1
Kutzner, H1
Kortz, A1
Carlson, JA1
Han, YM1
Sheng, YY1
Xu, F1
Qi, SS1
Liu, XJ1
Hu, RM1
Miao, Y1
Huang, GQ1
Yang, QP1
Chu, TW1
AlJasser, M1
Alharbi, A1
Abahussein, O1
McElwee, K1
Fawzi, MM1
Mahmoud, SB1
Shaker, OG1
Saleh, MA1
Lacarrubba, F2
Micali, G3
Bansal, M1
Kumar, A1
Bansal, A1
Fuentes-Duculan, J1
Gulati, N1
Bonifacio, KM1
Kunjravia, N1
Zheng, X1
Suárez-Fariñas, M1
Shemer, A1
Devi, M1
Rashid, A1
Ghafoor, R1
Jang, YH2
Moon, SY2
Lee, WJ2
Lee, SJ2
Lee, WK1
Park, BC1
Kim, H1
Kim, DW1
Pretzlaff, M1
Sulk, M1
Bähr, M1
Reibelt, M1
Kinori, M2
Bíró, T1
Lentini, M1
Palazzo, R1
Yoshimasu, T1
Kanazawa, N1
Yamamoto, Y1
Furukawa, F1
Ardigò, M2
Agozzino, M1
Franceschini, C1
Donadio, C1
Abraham, LS1
Barbieri, L1
Sperduti, I1
Berardesca, E2
González, S1
Jin, M1
Eun, DH1
Kim, MK1
Kim, SH1
Kim, do W1
Amer, M1
Helmy, A1
Amer, A1
Jun, M1
Lee, NR1
Cohen, BE1
Bashey, S1
Cole, C1
Abraham, JL1
Ragsdale, B1
Ngo, B1
Özdemir, M1
Balevi, A1
Khunkhet, S1
Vachiramon, V1
Pratt, CH1
King, LE1
Messenger, AG2
Sundberg, JP1
Fairhurst, DA1
Mitra, A1
MacDonald-Hull, S1
Jameel, K1
Ejaz, A1
Sohail, M1
Rahman, SB1
Meyer, KC2
Brzoska, T1
Abels, C1
Yun, SJ1
Kim, HS1
Choi, JY1
Lee, JB1
Kim, SJ1
Won, YH1
Lee, SC1
Yoo, KH1
Kim, MN1
Kim, BJ2
Kim, CW1
Talpur, R1
Vu, J1
Bassett, R1
Stevens, V1
Ali, A1
Martin, JM1
Ghoreishi, M1
Martinka, M2
Dutz, JP1
Guo, HW1
Deng, J1
Yang, XC1
Zhong, BY1
Shen, Z1
Yang, SY1
Liu, BH1
Hao, F1
Müller, CS1
El Shabrawi-Caelen, L1
Ohtsuki, A1
Hasegawa, T1
Ikeda, S1
Cho, HR1
Lew, H1
Alcántara González, J1
Truchuelo Díez, MT1
Carrillo Gijón, R1
Martín Diaz, RM1
Jaén Olasolo, P1
Cameli, N2
Vincenzi, C2
Misciali, C2
Takeichi, S1
Kubo, Y1
Murao, K1
Inoue, N1
Ansai, S1
Arase, S1
Cappel, JA1
Ioffreda, MD1
Kirby, JS1
Samuelov, L1
Emelianov, VU1
Hasse, S1
Khaled, A1
Hawilo, A1
Zaouak, A1
Zeglaoui, F1
Kharfi, M1
Kamoun, MR1
Kowalska-Oledzka, E1
Slowinska, M1
Czuwara, J1
Sicinska, J1
Heng, YK1
Ng, SK1
Tan, KB1
Lee, JS1
Samrao, A1
Fu, JM1
Harris, ST1
Price, VH2
Yano, S1
Nakamura, K1
Okochi, H1
Tamaki, K1
Török, L1
Gurbity, TP1
Kirschner, A1
Krenács, L1
Claude, V1
Blanchet, P1
Grossin, M1
Hénin, D1
Kaur, I1
Kumar, B1
Flores-Alvarado, DE1
Esquivel-Valerio, JA1
Garza-Elizondo, M1
Espinoza, LR1
Sharquie, KE1
Al-Waiz, MM1
Al-Nuaimy, AA1
Shum, DT1
Lui, H1
Bernardo, O1
Landau, M2
Assy, B3
Ullmann, Y2
Shalaginov, R2
Serafimovich, S2
Kalish, RS3
Shamsadini, S1
GOLDBERG, HC1
HANFLING, SL1
NEW, WN1
NICKEL, WR1
VAMOS, L1
WINKELMANN, RK1
JAFFE, MO1
BRAUN-FALCO, O2
HASSENPFLUG, K1
BORDA, JM1
ABULAFIA, J1
ALTERAS, I1
FALK, MS1
PRINGUET, R1
Trüeb, RM3
Whiting, DA2
NICHOLAS, L1
Skali, H1
El-Ghrari, K1
Benchikhi, H1
Lakhdar, H1
Ihm, CW2
Hong, SS1
Mun, JH1
Kim, HU1
Dall'Oglio, F1
Rita Nasca, M1
Mortazavi, M1
Mansouri, P1
Brajac, I1
Gruber, F1
Petrovecki, M1
Malnar-Dragojević, D1
KNIERER, W1
Lenane, P1
Pope, E1
Krafchik, B1
Chen, W1
Raulin, C1
Gündogan, C1
Greve, B1
Gebert, S1
Choi, HJ1
Rajaratnam, R1
Balasubramaniam, P1
Marsden, JR1
Choi, CW1
Park, ES1
Huh, CH1
Shamsadin, S1
Esfandiarpoor, I1
Zeinali, H1
Kalantari, B1
Ebrahimi, H1
Sohn, KC1
Jang, S1
Choi, DK1
Lee, YS1
Yoon, TJ1
Jeon, EK1
Park, JK1
Wasyłyszyn, T1
Kozłowski, W1
Zabielski, SL1
Inui, S1
Nakajima, T1
Itami, S1
Nnoruka, EN1
Obiagboso, I1
Maduechesi, C1
Dinh, QQ1
Chong, AH1
Ito, N1
Saatoff, M1
Hashizume, H1
Fukamizu, H1
Nickoloff, BJ1
Takigawa, M1
Whiting, D1
Iorizzo, M1
Pazzaglia, M1
Igarashi, R2
Takeuchi, S2
Sato, Y2
Tonkin, N2
Chavrakov, G1
Popkhistova, E1
Ranki, A1
Kianto, U1
Kanerva, L1
Tolvanen, E1
Johansson, E1
Todes-Taylor, N1
Turner, R1
Wood, GS1
Stratte, PT1
Morhenn, VB1
Klemp, P1
Lindskov, R2
Staberg, B1
Petkov, R1
Popkhristova, E1
Nunzi, E1
Hamerlinck, F1
Cormane, RH1
Bogdanowski, T1
Rubisz-Brzezinska, J1
Bader, C1
Laugier, P1
Mcdonagh, AJ1
Snowden, JA1
Stierle, C1
Elliott, K1
Watanabe, K1
Katayama, I1
Nishioka, K1
Nutbrown, M5
Hull, SP2
Cunliffe, WJ5
Randall, VA5
Tobin, DJ3
Bystryn, JC1
Szafer, F1
Oksenberg, JR1
Steinman, L1
Sawaya, ME1
Hordinsky, MK1
Calver, NS1
Parkin, SM1
Hoffmann, R3
Wenzel, E1
Huth, A1
van der Steen, P1
Schäufele, M1
Henninger, HP1
Happle, R5
Trakimas, C1
Sperling, LC2
Skelton, HG1
Smith, KJ1
Buker, JL1
Ostertag, JU1
Hulsmans, RF1
Neumann, HA1
Carson, HJ1
Pellettiere, EV1
Lack, E1
Tebbe, B1
Gollnick, H1
Müller, R1
Reupke, HJ1
Orfanos, CE1
Perriard-Wolfensberger, J1
Pasche-Koo, F1
Mainetti, C1
Labarthe, MP1
Salomon, D1
Saurat, JH1
Silvers, DN1
Katz, BE1
Young, AW1
Ruiz-Maldonado, R1
Tamayo, L1
Durán, C1
Böni, R1
Wüthrich, B1
La Placa, M1
Placucci, F1
Gentilomi, G1
Venturoli, S1
Zerbini, M1
Musiani, M1
MacDonald Hull, SP1
Baker, TG1
Baker, BS1
Powles, A1
Garioch, JJ1
Hardman, C1
Fry, L1
Rossi, R1
Del Bianco, E1
Isolani, D1
Baccari, MC1
Cappugi, P1
Elston, DM2
McCollough, ML2
Liranzo, MO1
Heibel, M1
Hernández-Cano, N1
Pizarro, A1
Lázaro, TE1
Mayor, M1
Burón, I1
Contreras, F1
Casado, M1
Berkutzki, T1
Yuen, YF1
Lewis, EJ1
Larson, JT1
Wilke, MS1
Rest, EB1
Zachary, CB1
Krasovec, M1
Hogan, P1
Ball, S1
Walkden, V1
Wojnarowska, F1
Freyschmidt-Paul, P1
Hamm, H1
Hoss, DM1
Grant-Kels, JM1
Hwang, SM1
Choi, EH1
Lee, SH1
Ahn, SK1
Itin, PH1
Schiller, P1
Alagna, G1
Bodemer, C1
Peuchmaur, M1
Fraitaig, S1
Chatenoud, L1
Brousse, N1
De Prost, Y1
Hedstrand, H1
Ekwall, O1
Haavik, J1
Landgren, E1
Betterle, C1
Perheentupa, J1
Gustafsson, J1
Husebye, E1
Rorsman, F1
Kämpe, O1
Tsuboi, H1
Tanei, R1
Fujimura, T1
Ohta, Y1
Katsuoka, K1
Clayton, AS1
Meffert, JJ1
Toyoda, M1
Kagoura, M1
Morohashi, M1
O'goshi, K1
Iguchi, M1
Tagami, H1
Akar, A1
Arca, E1
Erbil, H1
Akay, C1
Sayal, A1
Gür, AR1
Weigand, DA1
Cebulla, K1
Echternacht-Happle, K1
Szalay, A1
Nakajima, S1
Klaber, MR1
Munro, DD1
Stengel, F1
Ackerman, AB1
Franz, E1
Pierard, GE2
De la Brassinne, M1
Montes, LF1
Ceballos, R1
Fanti, PA1
Morelli, R1
Sabattini, E1
Pileri, S1
Winton, GB1
van Baar, HM2
Perret, CM2
van Vlijmen-Willems, IM1
Cleutjens, JP1
Mackie, EJ1
Schalkwijk, J2
Hull, SM2
Thornton, MJ2
Fenton, DA2
Kendall, MD2
Zaun, H1
Höring, E1
Wienbeck, M1
Cipriani, R1
Procidano, M1
Saltarin, P1
Girolami, A1
Peserico, A1
Tanii, T1
Okada, T1
Fukai, K1
Nakagawa, K1
Hamada, T1
Rebora, A1
Fransway, AF1
Muller, SA2
Baadsgaard, O1
Clemmensen, OJ1
Piérard-Franchimont, C1
Bekhor, PS1
Gibbons, RD1
Fiedler-Weiss, VC1
West, DP1
Lapin, G1
Krueger, GG1
Phillips, JH1
Smith, SL1
Storer, JS1
Csécsei, K1
Molnár, P1
Tóth, Z1
Papp, Z1
Williams, N1
Riegert, AL1
Selmanowitz, VJ1
Orentreich, N1
Beurey, J1
Weber, M1
Bertrand, A1
Robert, J1
Mabille, H1
Burgoyne, JS1
Hundeiker, M1
Tillmann, U1
Sanderson, KV1
Hall-Smith, P1
Helm, F1
Milgrom, H1
Hönemann, W1
Höfer, W1
Dupont, A1
Reginster, JP1
Boulond, A1
Popchristov, P1
Konstantinov, A1
Obreshkova, E1
Sorni, G1
Rassner, B1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA WITH A SINGLE-BLIND EXTENSION PERIOD AND A CROSS-OVER[NCT02974868]Phase 2142 participants (Actual)Interventional2016-12-15Completed
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata[NCT03800979]Phase 419 participants (Actual)Interventional2019-01-12Completed
Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata[NCT05600673]Phase 1/Phase 230 participants (Actual)Interventional2019-01-01Completed
Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis. Prospective, Multicenter Study (ETDT)[NCT02550496]104 participants (Actual)Interventional2015-03-04Completed
Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients[NCT03044782]34 participants (Actual)Observational [Patient Registry]2016-08-31Completed
The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945]Phase 430 participants (Anticipated)Interventional2021-04-01Not yet recruiting
A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata[NCT01520077]Phase 129 participants (Actual)Interventional2011-07-31Completed
Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation[NCT03473600]Phase 440 participants (Anticipated)Interventional2018-11-30Not yet recruiting
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata[NCT00999869]20 participants (Anticipated)Interventional2009-11-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1). (NCT02974868)
Timeframe: Baseline, Week24

Interventionunits on a scale (Least Squares Mean)
PF-0665160032.54
PF-0670084150.59
Placebo1.41

Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants

"SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were none at baseline." (NCT02974868)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
PF-06651600-AT/AU27.59
PF-06700841-AT/AU48.42
Placebo-AT/AU1.81

Percentage of Participants Achieving SALT 30 at Week 24

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Week 24

Interventionpercentage of participants (Number)
PF-0665160050.0
PF-0670084163.8
Placebo2.1

Change From Baseline in SALT Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionunit on a scale (Least Squares Mean)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516001.761.851.802.163.353.414.707.06
Active Non-responders on PF-067008410.092.223.163.013.193.122.973.01
Placebo Non-responders on PF-066516002.993.3710.168.9318.3025.7125.2828.88
Placebo Non-responders on PF-06700841-0.313.7124.6742.3250.2754.6962.4558.53
Retreated PF-06651600 Responders in the Retreatment Segment25.0427.6333.7838.8043.7048.9353.7455.94
Retreated Responders on PF-06700841 in the Retreatment Segment19.8315.6620.0927.3539.2850.5853.7958.37

Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionunits on a scale (Least Squares Mean)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-06651600-0.742.9312.4418.4924.4927.5929.3231.14
PF-06700841-0.937.7019.3729.3036.5741.1645.5549.18
Placebo1.180.851.321.771.621.611.621.41

Number of Participants With Laboratory Abnormalities During SBE Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)

,,,,,,,,,
InterventionParticipants (Count of Participants)
With abnormalities without regard to baselineMeeting Retest CriteriaMeeting Discontinuation Criteria
Active Non-responders on PF-066516001330
Active Non-responders on PF-06700841420
Non-Retreated PF-06651600 Responders in the Withdrawal Segment620
Non-Retreated PF-06700841 Responders in the Withdrawal Segment730
Placebo Non-responders on PF-066516001150
Placebo Non-responders on PF-067008411170
Retreated PF-06651600 Responders in the Retreatment Segment1141
Retreated PF-06651600 Responders in the Withdrawal Segment900
Retreated PF-06700841 Responders in the Withdrawal Segment1020
Retreated Responders on PF-06700841 in the Retreatment Segment1440

Number of Participants With Laboratory Abnormalities During Treatment Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: Baseline up to Week 24

,,
InterventionParticipants (Count of Participants)
With abnormalities without regard to baselineMeeting Safety CriteriaMeeting Retest CriteriaMeeting Discontinuation Criteria
PF-06651600351250
PF-067008413629183
Placebo32590

Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. (NCT02974868)
Timeframe: COE day 1 up to end of study

,
InterventionParticipants (Count of Participants)
TEAE (All Causalities)TEAE (Treatment Related)
COE-PF-0665160042
COE-PF-0670084193

Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period

"An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with withdrawal Segment and retreatment segment described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment." (NCT02974868)
Timeframe: Week 28 up to Week 52

,,,,,,,,,
InterventionParticipants (Count of Participants)
TEAE (All Causalities)TEAE (Treatment Related)
Active Non-responders on PF-0665160085
Active Non-responders on PF-0670084140
Non-Retreated PF-06651600 Responders in the Withdrawal Segment40
Non-Retreated PF-06700841 Responders in the Withdrawal Segment60
Placebo Non-responders on PF-06651600121
Placebo Non-responders on PF-06700841101
Retreated PF-06651600 Responders in the Retreatment Segment112
Retreated PF-06651600 Responders in the Withdrawal Segment31
Retreated PF-06700841 Responders in the Withdrawal Segment93
Retreated Responders on PF-06700841 in the Retreatment Segment92

Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. (NCT02974868)
Timeframe: baseline up to Week 24

,,
InterventionParticipants (Count of Participants)
TEAE (All Causalities)TEAE (Treatment Related)
PF-066516003213
PF-067008413620
Placebo3514

Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: COE day 1 up to end of study

,
InterventionParticipants (Count of Participants)
With abnormalities without regard to baselineMeeting Retest CriteriaMeeting Discontinuation Criteria
COE-PF-06651600510
COE-PF-067008411160

Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercent change (Least Squares Mean)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-06651600-0.763.9915.8823.2230.9935.1437.3139.67
PF-06700841-1.139.7022.8834.7844.1749.9955.4659.71
Placebo1.260.531.021.310.990.860.910.43

Percentage of Participants Achieving SALT 100 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionpercentage of participants (Number)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516000.00.00.00.00.00.00.00.0
Active Non-responders on PF-067008410.00.00.00.00.00.00.00.0
Placebo Non-responders on PF-066516000.00.00.00.00.00.00.00.0
Placebo Non-responders on PF-067008410.00.00.00.08.38.38.38.3
Retreated PF-06651600 Responders in the Retreatment Segment0.00.00.00.07.17.17.114.3
Retreated Responders on PF-06700841 in the Retreatment Segment0.00.00.00.00.013.320.020.0

Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-066516000.00.00.00.02.12.14.212.5
PF-067008410.00.00.02.16.48.512.812.8
Placebo00000000

Percentage of Participants Achieving SALT 30 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionpercent of participants (Number)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516004.14.14.14.110.410.410.410.4
Active Non-responders on PF-06700841-2.1-2.1-2.1-2.1-2.1-2.1-2.1-2.1
Placebo Non-responders on PF-066516003.89.621.421.427.333.239.027.3
Placebo Non-responders on PF-06700841-2.114.531.256.281.264.564.564.5
Retreated PF-06651600 Responders in the Retreatment Segment47.962.269.369.362.262.269.355.0
Retreated Responders on PF-06700841 in the Retreatment Segment31.211.231.244.551.251.251.251.2

Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-06651600-2.16.218.725.039.545.847.947.9
PF-06700841-2.112.827.738.348.955.359.661.7
Placebo2.12.12.12.12.12.12.12.1

Percentage of Participants Achieving SALT 50 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionpercentage of participants (Number)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516000.00.0-2.1-2.1-2.1-2.14.14.1
Active Non-responders on PF-067008410.00.0-2.1-2.1-2.1-2.1-2.1-2.1
Placebo Non-responders on PF-066516000.00.09.63.815.521.427.327.3
Placebo Non-responders on PF-067008410.00.031.256.256.264.564.564.5
Retreated PF-06651600 Responders in the Retreatment Segment14.321.426.433.647.947.947.947.9
Retreated Responders on PF-06700841 in the Retreatment Segment20.06.711.224.544.544.537.944.5

Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-066516000.00.010.418.727.033.333.337.5
PF-067008410.010.617.029.836.240.446.851.1
Placebo002.12.12.12.12.12.1

Percentage of Participants Achieving SALT 75 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionpercentage of participants (Number)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516000.00.00.0-2.1-2.1-2.1-2.14.1
Active Non-responders on PF-067008410.00.00.0-2.1-2.1-2.1-2.1-2.1
Placebo Non-responders on PF-066516000.00.00.0-2.13.815.515.527.3
Placebo Non-responders on PF-067008410.00.08.322.939.556.264.564.5
Retreated PF-06651600 Responders in the Retreatment Segment0.07.114.326.426.426.428.633.6
Retreated Responders on PF-06700841 in the Retreatment Segment0.00.06.717.931.237.937.937.9

Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-066516000.00.08.312.516.620.825.027.0
PF-067008410.00.010.623.427.731.938.340.4
Placebo0002.12.12.12.12.1

Percentage of Participants Achieving SALT 90 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

,,,,,
Interventionpercentage of participants (Number)
Week 30/ AT Week 2Week 32/ AT Week 4Week 34/ AT Week 6Week 36/ AT Week 8Week 40/ AT Week 12Week 44/ AT Week 16Week 48/ AT Week 20Week 52/ AT Week 24
Active Non-responders on PF-066516000.00.00.00.00.00.0-2.10.0
Active Non-responders on PF-067008410.00.00.00.00.00.0-2.10.0
Placebo Non-responders on PF-066516000.00.00.00.00.00.03.817.6
Placebo Non-responders on PF-067008410.00.00.08.325.033.347.950.0
Retreated PF-06651600 Responders in the Retreatment Segment0.00.00.07.114.321.426.428.6
Retreated Responders on PF-06700841 in the Retreatment Segment0.00.00.06.713.320.024.540.0

Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24

,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8Week 12Week 16Week 20Week 24
PF-066516000.00.00.04.210.416.718.725.0
PF-067008410.00.06.412.825.527.729.834.0
Placebo0000002.10

Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)

Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis. (NCT02974868)
Timeframe: Week 24 up to Week 52

,
InterventionWeeks (Number)
Q1 time to retreatment (25th percentile of time)Median time to retreatmentQ3 time to retreatment (75th percentile of time)
PF-06651600 Responders10.116.121.1
PF-06700841 Responders11.024.1NA

Number of Participants With the IGA Score Change (Treatment Period)

The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1). (NCT02974868)
Timeframe: baseline, Week 2,4,6,8,12,16,20,24

InterventionParticipants (Count of Participants)
Baseline72539794Baseline72539793Baseline72539795Week 272539793Week 272539794Week 272539795Week 472539793Week 472539794Week 472539795Week 672539793Week 672539794Week 672539795Week 872539793Week 872539795Week 872539794Week 1272539794Week 1272539795Week 1272539793Week 1672539793Week 1672539794Week 1672539795Week 2072539793Week 2072539794Week 2072539795Week 2472539793Week 2472539794Week 2472539795
0 (NO CHANGE OR FURTHER LOSS)1 (1-24% REGROWTH)2 (25-49% REGROWTH)3 (50-74% REGROWTH)4 (75-99% REGROWTH)5 (100% REGROWTH)
PF-0665160048
PF-0670084147
Placebo47
PF-0665160040
PF-0670084143
Placebo40
Placebo5
PF-066516000
PF-067008410
PF-0665160029
PF-0670084121
Placebo36
PF-0665160015
PF-0670084119
PF-067008412
PF-0665160016
PF-0670084110
Placebo35
PF-0665160018
PF-0670084117
Placebo6
PF-067008419
PF-066516002
Placebo33
PF-0665160017
Placebo9
PF-067008413
Placebo1
PF-067008411
Placebo0
PF-0665160011
Placebo10
PF-066516009
Placebo31
PF-066516001
PF-0665160014
Placebo29
PF-067008416
PF-066516008
PF-067008417
PF-066516004
PF-0665160010
PF-0670084111
PF-066516003
PF-067008418
PF-0665160013
PF-067008414
Placebo27
PF-066516005
PF-066516007
PF-067008415
PF-0670084113
PF-066516006

Side Effects From Tofacitinib

Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48. (NCT03800979)
Timeframe: 48 weeks

Interventionparticipants (Number)
DyslipidemiaUpper respiratory tract infectionTuberculosisMyalgiaAcneWeight gainConstipation
Tofacitinib9611211

Reviews

28 reviews available for salicylic acid and Alopecia Circumscripta

ArticleYear
[Janus kinase inhibitors for the treatment of alopecia areata].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2022, Volume: 73, Issue:5

    Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase Inhibitors; Quality of Life; Scalp

2022
Trichoscopy beyond scalp. A narrative review.
    International journal of dermatology, 2023, Volume: 62, Issue:3

    Topics: Alopecia Areata; Eyebrows; Hair; Humans; Scalp; Scalp Dermatoses

2023
Alopecia Areata: Current Treatments and New Directions.
    American journal of clinical dermatology, 2023, Volume: 24, Issue:6

    Topics: Alopecia; Alopecia Areata; Hair Follicle; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors;

2023
Alopecia Areata: The Clinician and Patient Voice.
    Journal of drugs in dermatology : JDD, 2023, Oct-01, Volume: 22, Issue:10

    Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Hair Follicle; Humans; Recurrence; Scalp

2023
Common causes of hair loss - clinical manifestations, trichoscopy and therapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:3

    Topics: Alopecia; Alopecia Areata; Hair Diseases; Humans; Lichen Planus; Scalp; Trichotillomania

2021
Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.
    American journal of clinical dermatology, 2018, Volume: 19, Issue:5

    Topics: Alopecia Areata; Antimalarials; Dermatologic Agents; Dermoscopy; Diagnosis, Differential; Disease Pr

2018
Alopecia areata: A multifactorial autoimmune condition.
    Journal of autoimmunity, 2019, Volume: 98

    Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Animals; Autoimmunity; Cell Movement; Gene-Envir

2019
The role of the microbiome in scalp hair follicle biology and disease.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Alopecia; Alopecia Areata; Animals; Dermatitis, Seborrheic; Hair; Hair Follicle; Humans; Immune Syst

2020
Alopecia areata: more than skin deep.
    The Practitioner, 2013, Volume: 257, Issue:1764

    Topics: Alopecia Areata; Global Health; Hair; Humans; Prevalence; Scalp

2013
Hair loss in autoimmune systemic diseases.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:1

    Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Cicatrix; Connective Tissue Diseases; Hair Diseases;

2014
Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research.
    Dermatologic clinics, 2014, Volume: 32, Issue:2

    Topics: Alopecia Areata; Black or African American; Cicatrix; Female; Humans; Prevalence; Risk Factors; Scal

2014
Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:3

    Topics: Alopecia; Alopecia Areata; Beauty Culture; Diagnosis, Differential; Humans; Hyperandrogenism; Physic

2014
Circumscribed cicatricial alopecia due to localized sarcoidal granulomas and single-organ granulomatous arteritis: a case report and systematic review of sarcoidal vasculitis.
    Journal of cutaneous pathology, 2015, Volume: 42, Issue:10

    Topics: Acyclovir; Adult; Aged; Alopecia Areata; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B

2015
Evaluation of hair loss.
    Current problems in dermatology, 2015, Volume: 47

    Topics: Alopecia; Alopecia Areata; Biopsy; Dermatitis, Seborrheic; Dermoscopy; Female; Hair Diseases; Humans

2015
Scalp dermoscopy or trichoscopy.
    Current problems in dermatology, 2015, Volume: 47

    Topics: Alopecia; Alopecia Areata; Cicatrix; Dermoscopy; Hair Diseases; Humans; Lupus Erythematosus, Discoid

2015
Alopecia areata.
    Nature reviews. Disease primers, 2017, Mar-16, Volume: 3

    Topics: Alopecia Areata; Environmental Exposure; Hair; Hair Follicle; Humans; Microbiota; Scalp; Stress, Psy

2017
Coexistence of giant blue nevus of the scalp with hair loss and alopecia areata.
    The Journal of dermatology, 2011, Volume: 38, Issue:4

    Topics: Adult; Alopecia Areata; Humans; Male; Nevus, Blue; Scalp; Skin Neoplasms; Tomography, X-Ray Computed

2011
Ant-induced alopecia: report of 2 cases and review of the literature.
    Dermatology online journal, 2004, Jul-15, Volume: 10, Issue:1

    Topics: Adult; Alopecia; Alopecia Areata; Animals; Ants; Appetitive Behavior; Bedding and Linens; Diagnosis,

2004
Congenital alopecia areata.
    Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:2 Suppl 1

    Topics: Administration, Cutaneous; Alopecia Areata; Eyebrows; Eyelashes; Female; Follow-Up Studies; Glucocor

2005
Alopecia neoplastica simulating alopecia areata and antedating the detection of primary breast carcinoma.
    Journal of cutaneous pathology, 1994, Volume: 21, Issue:1

    Topics: Adult; Alopecia; Alopecia Areata; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Scalp;

1994
Does interleukin-1 induce hair loss?
    Dermatology (Basel, Switzerland), 1995, Volume: 191, Issue:4

    Topics: Alopecia Areata; Animals; Gene Expression Regulation; Hair; Humans; Immunologic Factors; Interleukin

1995
Scalp metastases mimicking alopecia areata. First case report of placental site trophoblastic tumor presenting as cutaneous metastasis.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 1998, Volume: 24, Issue:5

    Topics: Adult; Alopecia Areata; Diagnosis, Differential; Female; Humans; Postpartum Period; Pregnancy; Scalp

1998
Cicatricial pemphigoid rarely involves the scalp.
    The Australasian journal of dermatology, 1998, Volume: 39, Issue:4

    Topics: Alopecia Areata; Biopsy; Female; Humans; Middle Aged; Pemphigoid, Benign Mucous Membrane; Scalp; Tre

1998
Double-lined frontoparietal scleroderma en coup de sabre.
    Dermatology (Basel, Switzerland), 1999, Volume: 199, Issue:2

    Topics: Adult; Alopecia Areata; Female; Humans; Scalp; Scleroderma, Localized

1999
Recent developments in alopecias.
    International journal of dermatology, 1978, Volume: 17, Issue:4

    Topics: Alopecia; Alopecia Areata; Androgens; Dihydrotestosterone; Female; Humans; Male; Protein-Energy Maln

1978
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
    Cutis, 1988, Volume: 41, Issue:6

    Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B

1988
Common hair disorders.
    Australian family physician, 1986, Volume: 15, Issue:7

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Humans; Male; Nevus, Pigmented; Scalp; Skin Neoplas

1986
Alopecia: syndromes of genetic significance.
    The Journal of investigative dermatology, 1973, Volume: 60, Issue:6

    Topics: Abnormalities, Multiple; Adolescent; Adult; Age Factors; Alopecia; Alopecia Areata; Child; Child, Pr

1973

Trials

17 trials available for salicylic acid and Alopecia Circumscripta

ArticleYear
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
    The Journal of allergy and clinical immunology, 2022, Volume: 149, Issue:4

    Topics: Alopecia; Alopecia Areata; Biomarkers; Humans; Janus Kinase Inhibitors; Protein Kinase Inhibitors; S

2022
The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
    Dermatologic therapy, 2022, Volume: 35, Issue:6

    Topics: Alopecia; Alopecia Areata; Double-Blind Method; Humans; Latanoprost; Scalp; Treatment Outcome

2022
The role of autologous micrografts injection from the scalp tissue in the treatment of COVID-19 associated telogen effluvium: Clinical and trichoscopic evaluation.
    Dermatologic therapy, 2022, Volume: 35, Issue:7

    Topics: Adult; Alopecia Areata; Autografts; COVID-19; Follow-Up Studies; Hair Follicle; Humans; Microsurgery

2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
    Allergy, 2023, Volume: 78, Issue:4

    Topics: Alopecia Areata; Biomarkers; Humans; Keratins, Hair-Specific; Scalp; Virulence

2023
Use of vibrating anesthetic device reduces the pain of mesotherapy injections: A randomized split-scalp study.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:2

    Topics: Alopecia; Alopecia Areata; Anesthetics; Child; Humans; Mesotherapy; Pain; Scalp

2021
A randomized, placebo and active controlled, split scalp study to evaluate the efficacy of platelet-rich plasma in patchy alopecia areata of the scalp.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Alopecia Areata; Humans; Platelet-Rich Plasma; Scalp; Treatment Outcome; Triamcinolone Acetonide

2020
Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial.
    Dermatologic therapy, 2021, Volume: 34, Issue:1

    Topics: Alopecia Areata; Humans; Injections, Intralesional; Scalp; Treatment Outcome; Triamcinolone Acetonid

2021
Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety.
    Photodiagnosis and photodynamic therapy, 2021, Volume: 36

    Topics: Alopecia Areata; Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Scalp; Tre

2021
Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study.
    Dermatology (Basel, Switzerland), 2015, Volume: 230, Issue:4

    Topics: Administration, Cutaneous; Adult; Alopecia Areata; Bimatoprost; Dermatologic Agents; Female; Hair; H

2015
Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study.
    Journal of the American Academy of Dermatology, 2015, Volume: 73, Issue:2

    Topics: Adult; Alopecia Areata; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S

2015
Intralesional Triamcinolone Acetonide Versus Topical Betamethasone Valearate in the Management of Localized Alopecia Areata.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:12

    Topics: Administration, Topical; Adult; Alopecia Areata; Betamethasone Valerate; Female; Follow-Up Studies;

2015
Multiple courses of pulse corticosteroid therapy for alopecia areata.
    The Journal of dermatology, 2016, Volume: 43, Issue:9

    Topics: Administration, Intravenous; Adolescent; Adult; Alopecia Areata; Female; Glucocorticoids; Hair; Huma

2016
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
    Pediatric dermatology, 2017, Volume: 34, Issue:2

    Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Child; Chronic Disease; Dermatologi

2017
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.
    Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Anticarcinogenic Agents; Bexarote

2009
Treatment effects of intradermal botulinum toxin type A injection on alopecia areata.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010, Volume: 36 Suppl 4

    Topics: Adolescent; Adult; Alopecia Areata; Botulinum Toxins, Type A; Child; Female; Humans; Injections, Int

2010
Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone.
    The Journal of investigative dermatology, 1994, Volume: 103, Issue:4

    Topics: Adult; Aged; Allergens; Alopecia Areata; Biopsy; Chromatography, High Pressure Liquid; Cyclopropanes

1994
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
    Cutis, 1988, Volume: 41, Issue:6

    Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B

1988

Other Studies

251 other studies available for salicylic acid and Alopecia Circumscripta

ArticleYear
Resident human dermal γδT-cells operate as stress-sentinels: Lessons from the hair follicle.
    Journal of autoimmunity, 2021, Volume: 124

    Topics: Adult; Aged; Alopecia Areata; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Autoim

2021
Characterizing the willingness to undergo treatment in patients with alopecia areata.
    Archives of dermatological research, 2022, Volume: 314, Issue:8

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Hair; Humans; Scalp

2022
Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom?
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:1

    Topics: Alopecia; Alopecia Areata; Female; Ferritins; Hemoglobins; Humans; Male; Retrospective Studies; Scal

2022
Telogen Effluvium as a complication of scalp reconstruction with tissue expander: a case report.
    Acta bio-medica : Atenei Parmensis, 2021, 10-27, Volume: 92, Issue:S1

    Topics: Alopecia Areata; Female; Humans; Scalp; Surgical Flaps; Tissue Expansion; Tissue Expansion Devices

2021
A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
    The British journal of dermatology, 2022, Volume: 186, Issue:5

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Female; Hair; Humans; Male; Nail Diseases; Patient Rep

2022
Alopecia areata - Current understanding and management.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:1

    Topics: Alopecia; Alopecia Areata; Humans; Immunotherapy; Quality of Life; Recurrence; Scalp

2022
Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Alopecia Areata; Hair; Humans; Quality of Life; Scalp

2023
Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp.
    The American Journal of dermatopathology, 2022, Nov-01, Volume: 44, Issue:11

    Topics: Alopecia; Alopecia Areata; Glycyrrhizic Acid; Humans; Lipedema; Minoxidil; Scalp; Vitamin D

2022
Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Child; Child, Preschool; Fema

2023
Annular plaque over the scalp with patchy alopecia.
    International journal of dermatology, 2023, Volume: 62, Issue:4

    Topics: Alopecia; Alopecia Areata; Humans; Scalp; Scalp Dermatoses

2023
The First Evidence of Bacterial Foci in the Hair Part and Dermal Papilla of Scalp Hair Follicles: A Pilot Comparative Study in Alopecia Areata.
    International journal of molecular sciences, 2022, Oct-08, Volume: 23, Issue:19

    Topics: Adult; Alopecia Areata; Hair Follicle; Humans; Microbiota; Middle Aged; Scalp; Young Adult

2022
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
    Skin pharmacology and physiology, 2023, Volume: 36, Issue:2

    Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp

2023
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
    Skin pharmacology and physiology, 2023, Volume: 36, Issue:2

    Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp

2023
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
    Skin pharmacology and physiology, 2023, Volume: 36, Issue:2

    Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp

2023
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
    Skin pharmacology and physiology, 2023, Volume: 36, Issue:2

    Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp

2023
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
    JAMA dermatology, 2023, 02-01, Volume: 159, Issue:2

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp

2023
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
    JAMA dermatology, 2023, 02-01, Volume: 159, Issue:2

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp

2023
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
    JAMA dermatology, 2023, 02-01, Volume: 159, Issue:2

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp

2023
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
    JAMA dermatology, 2023, 02-01, Volume: 159, Issue:2

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp

2023
Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:8

    Topics: Alopecia Areata; COVID-19; Humans; Scalp

2023
Granuloma annulare with alopecia areata in a 6-year-old girl: a case report.
    Journal of medical case reports, 2023, May-11, Volume: 17, Issue:1

    Topics: Alopecia Areata; Child; Female; Glucocorticoids; Granuloma Annulare; Humans; Scalp

2023
Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series.
    The American Journal of dermatopathology, 2023, Jul-01, Volume: 45, Issue:7

    Topics: Alopecia; Alopecia Areata; Cicatrix; Humans; Lichen Planus; Sarcoidosis; Scalp

2023
Integrated single-cell chromatin and transcriptomic analyses of human scalp identify gene-regulatory programs and critical cell types for hair and skin diseases.
    Nature genetics, 2023, Volume: 55, Issue:8

    Topics: Alopecia Areata; Chromatin; Eczema; Genome-Wide Association Study; Hair Follicle; Humans; Scalp; Tra

2023
Diagnosis and differential diagnosis of tertiary androgenetic alopecia with severe alopecia areata based on high-resolution MRI.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:7

    Topics: Alopecia; Alopecia Areata; Diagnosis, Differential; Hair Follicle; Humans; Magnetic Resonance Imagin

2023
Adjuvant Scalp Rolling for Patients With Refractory Alopecia Areata.
    Cutis, 2023, Volume: 112, Issue:1

    Topics: Adjuvants, Immunologic; Alopecia Areata; Humans; Scalp

2023
Immunohistochemistry of a cellular infiltrate in a case of nivolumab-induced alopecia areata.
    European journal of dermatology : EJD, 2023, 08-01, Volume: 33, Issue:4

    Topics: Alopecia Areata; Humans; Immunohistochemistry; Nivolumab; Scalp

2023
There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib.
    The British journal of dermatology, 2023, 11-16, Volume: 189, Issue:6

    Topics: Alopecia Areata; Hair; Humans; Scalp

2023
Increased expression of TLR7 and TLR9 in alopecia areata.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Adult; Alopecia Areata; Autoimmune Diseases; Biopsy; Female; Hair Follicle; Humans; Interferon-gamma

2020
Combined and dynamic trichoscopic signs for diagnosis and follow-up of inflammatory tinea capitis.
    The Australasian journal of dermatology, 2020, Volume: 61, Issue:1

    Topics: Alopecia Areata; Antifungal Agents; Child, Preschool; Female; Humans; Scalp; Tinea Capitis; Treatmen

2020
Response of alopecia areata of the beard to oral tofacitinib.
    Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:5

    Topics: Administration, Oral; Adult; Aged; Alopecia Areata; Cheek; Chin; Humans; Janus Kinases; Male; Middle

2020
Long-standing patchy alopecia areata along the hairline, a variety of alopecia areata mimicking frontal fibrosing alopecia and other cases of hair loss: case series of 11 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:4

    Topics: Adult; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Scalp

2020
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
    The British journal of dermatology, 2020, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Hair; Humans; Scalp

2020
Local secretion of stress hormones increases in alopecia areata lesions after treatment with UVA-1 phototherapy.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Adrenocorticotropic Hormone; Adult; Alopecia Areata; alpha-MSH; Biopsy; Corticotropin-Releasing Horm

2020
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
    The British journal of dermatology, 2020, Volume: 183, Issue:6

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Hair; Humans; North America; Patient Reported Outcome

2020
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
    The British journal of dermatology, 2020, Volume: 183, Issue:6

    Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase 3; Lichen Planus; Quality of Life; Scalp

2020
Percentage of scalp-hair loss as a primary endpoint in alopecia areata trials.
    The British journal of dermatology, 2020, Volume: 183, Issue:4

    Topics: Alopecia Areata; Hair Follicle; Humans; Scalp

2020
Predictive Metagenomic Profiling, Urine Metabolomics, and Human Marker Gene Expression as an Integrated Approach to Study Alopecia Areata.
    Frontiers in cellular and infection microbiology, 2020, Volume: 10

    Topics: Alopecia Areata; Biomarkers; Gene Expression; Humans; Metabolomics; Scalp

2020
Massive Acute Alopecia of the Scalp in a Patient Treated with Dupilumab.
    Acta dermato-venereologica, 2020, Jun-18, Volume: 100, Issue:13

    Topics: Alopecia Areata; Antibodies, Monoclonal, Humanized; Humans; Scalp

2020
A new self-reported measure of disease severity of scalp hair loss in alopecia areata.
    The British journal of dermatology, 2020, Volume: 183, Issue:6

    Topics: Alopecia; Alopecia Areata; Hair; Humans; Scalp; Self Report; Severity of Illness Index

2020
Clinically Applicable Deep Learning Framework for Measurement of the Extent of Hair Loss in Patients With Alopecia Areata.
    JAMA dermatology, 2020, 09-01, Volume: 156, Issue:9

    Topics: Alopecia Areata; Deep Learning; Hair; Humans; Image Processing, Computer-Assisted; Photography; Prog

2020
Exome sequencing reveals novel candidate gene variants associated with clinical characteristics in alopecia areata patients.
    Journal of dermatological science, 2020, Volume: 99, Issue:3

    Topics: Acyltransferases; Adolescent; Age of Onset; Alopecia; Alopecia Areata; Child; Chloride Channels; Exo

2020
Does dysfunctional autophagy contribute to immune privilege collapse and alopecia areata pathogenesis?
    Journal of dermatological science, 2020, Volume: 100, Issue:1

    Topics: Adult; Alopecia Areata; Apoptosis; Autophagy; Biopsy; Case-Control Studies; Dietary Supplements; Fem

2020
Expression of survivin and p53 genes in patients with alopecia areata: A case-control study.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy, Needle; Case-Control Studies; Female; Genes, p53; Humans

2021
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2020, Volume: 68, Issue:7

    Topics: Alopecia Areata; Gastrointestinal Microbiome; Genomics; Humans; Microbiota; Scalp

2020
Scalp sarcoidosis with alopecia areata showing Renbök phenomenon.
    The Journal of dermatology, 2020, Volume: 47, Issue:12

    Topics: Alopecia; Alopecia Areata; Humans; Psoriasis; Sarcoidosis; Scalp

2020
[Regulatory T cells control hair growth and prevent the development of alopecia areata].
    Medecine sciences : M/S, 2020, Volume: 36, Issue:10

    Topics: Alopecia Areata; Hair; Hair Follicle; Humans; Scalp; Skin Physiological Phenomena; T-Lymphocytes, Re

2020
Trichoscopy of Alopecia Areata: Hair Loss Feature Extraction and Computation Using Grid Line Selection and Eigenvalue.
    Computational and mathematical methods in medicine, 2020, Volume: 2020

    Topics: Algorithms; Alopecia Areata; Computational Biology; Dermoscopy; Disease Progression; Hair; Hair Foll

2020
Role of adiponectin and leptin in patients with alopecia areata with scalp hair loss.
    Irish journal of medical science, 2021, Volume: 190, Issue:3

    Topics: Adiponectin; Alopecia Areata; Body Mass Index; Case-Control Studies; Female; Humans; Insulin Resista

2021
Eyebrows Are Important in the Treatment of Alopecia Areata.
    The journal of investigative dermatology. Symposium proceedings, 2020, Volume: 20, Issue:1

    Topics: Adult; Alopecia Areata; Eyebrows; Female; Hair; Humans; Male; Middle Aged; Patient Care Planning; Pa

2020
Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series.
    The journal of investigative dermatology. Symposium proceedings, 2020, Volume: 20, Issue:1

    Topics: Aged; Alopecia; Alopecia Areata; Biological Factors; Female; Hair; Humans; Male; Middle Aged; Platel

2020
The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.
    The journal of investigative dermatology. Symposium proceedings, 2020, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Alopecia Areata; Endpoint Determination; Extremities; Eye Diseases; Eyebrow

2020
Co-localization of alopecia areata and lichen planopilaris in a patient receiving immunosuppressants: A rare case.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:3

    Topics: Adult; Alopecia; Alopecia Areata; Female; Hair Follicle; Humans; Immunosuppressive Agents; Lichen Pl

2021
Scalp Micropigmentation Procedure: A Useful Procedure for Hair Restoration.
    The Journal of craniofacial surgery, 2021, May-01, Volume: 32, Issue:3

    Topics: Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Scalp; Tattooing

2021
Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP/OX40L/IL-13 pathway in severe alopecia areata.
    Experimental dermatology, 2021, Volume: 30, Issue:2

    Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia Areata; Child; Cyclopropanes; Cytokines; Derm

2021
Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium.
    Dermatologic therapy, 2021, Volume: 34, Issue:2

    Topics: Alopecia; Alopecia Areata; Female; Hair; Humans; Italy; Male; Middle Aged; Scalp

2021
Lesson to Learn From Cellular infiltrate in Scalp Biopsy of Alopecia Areata.
    The American Journal of dermatopathology, 2021, Dec-01, Volume: 43, Issue:12

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Female; Humans; Male; Middle Aged; Scalp; Young Adult

2021
An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata.
    Allergy, 2021, Volume: 76, Issue:10

    Topics: Alopecia Areata; Biomarkers; Humans; Keratins, Hair-Specific; Keratins, Type II; Lymphocyte Activati

2021
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
    Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:3

    Topics: Alopecia; Alopecia Areata; Biomarkers; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Pla

2022
Alopecia areata severity index (AASI): A reliable scoring system to assess the severity of alopecia areata on face and scalp-a pilot study.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:8

    Topics: Alopecia Areata; Hair; Humans; Pilot Projects; Reproducibility of Results; Scalp

2021
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:12

    Topics: Alopecia; Alopecia Areata; Female; Humans; Lichen Planus; Middle Aged; Retrospective Studies; Scalp;

2021
Lupus erythematosus tumidus of the scalp masquerading as alopecia areata.
    Cutis, 2017, Volume: 99, Issue:2

    Topics: Alopecia Areata; Biopsy; Female; Humans; Lupus Erythematosus, Discoid; Middle Aged; Scalp

2017
Treatment of Alopecia Areata With Tofacitinib.
    JAMA dermatology, 2017, 06-01, Volume: 153, Issue:6

    Topics: Adult; Alopecia Areata; Female; Follow-Up Studies; Hair; Humans; Male; Middle Aged; Piperidines; Pol

2017
Pediatric severity of alopecia tool.
    Pediatric dermatology, 2018, Volume: 35, Issue:1

    Topics: Adolescent; Alopecia Areata; Child; Child, Preschool; Disease Progression; Female; Hair; Humans; Mal

2018
Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm.
    International journal of dermatology, 2018, Volume: 57, Issue:2

    Topics: Adult; Alopecia Areata; Biopsy; Case-Control Studies; Female; Hair Follicle; Humans; Male; Prospecti

2018
Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation.
    The journal of investigative dermatology. Symposium proceedings, 2018, Volume: 19, Issue:1

    Topics: Algorithms; Alopecia Areata; Child; Diagnosis, Computer-Assisted; Female; Hair; Humans; Image Proces

2018
Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:6

    Topics: Alopecia Areata; Biopsy; Case-Control Studies; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans;

2018
Adalimumab-related alopecia in a patient affected by psoriasis.
    Dermatology online journal, 2017, Jul-15, Volume: 23, Issue:7

    Topics: Adalimumab; Alopecia; Alopecia Areata; Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Hu

2017
Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy.
    Journal of cosmetic dermatology, 2018, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Age Factors; Alopecia Areata; Case-Control Studies; Child; Female; Humans; Interl

2018
An integrated model of alopecia areata biomarkers highlights both T
    The Journal of allergy and clinical immunology, 2018, Volume: 142, Issue:5

    Topics: Adult; Aged; Alopecia Areata; Biomarkers; Cytokines; Female; Humans; Male; Middle Aged; Scalp; Th1 C

2018
Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata.
    Dermatology (Basel, Switzerland), 2018, Volume: 234, Issue:3-4

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Cross-Sectional Studies; Female; Hair Follicle

2018
Morphological classification system of hair regrowth patterns in alopecia areata patches: DIMT classification.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:3

    Topics: Alopecia Areata; Hair; Humans; Photography; Retrospective Studies; Scalp

2019
High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.
    JCI insight, 2018, 10-04, Volume: 3, Issue:19

    Topics: Adolescent; Adult; Alopecia Areata; Animals; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Diseas

2018
Sequential cyclic changes of hair roots revealed by dermoscopy demonstrate a progressive mechanism of diffuse alopecia areata over time.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Case-Control Studies; Dermoscopy; Female; Hair

2020
Cellular retinol-binding protein-1 expression increases with increasing clinical severity of alopecia areata.
    Journal of cosmetic dermatology, 2019, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Case-Control Studies; Child; Female; Humans; Male; Middl

2019
A prospective study of tinea capitis in children: making the diagnosis easier with a dermoscope.
    Journal of medical case reports, 2018, Dec-28, Volume: 12, Issue:1

    Topics: Adolescent; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Hair; Humans; Male; Prospe

2018
Rule of thumb: A simple tool to estimate 1% scalp surface area.
    Journal of the American Academy of Dermatology, 2019, Volume: 81, Issue:2

    Topics: Adult; Alopecia Areata; Body Surface Area; Clinical Trials as Topic; Dermatology; Female; Humans; Ma

2019
Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient.
    The Journal of dermatology, 2019, Volume: 46, Issue:5

    Topics: Adult; Alopecia Areata; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Hair; Humans; Scalp

2019
Scalp bacterial shift in Alopecia areata.
    PloS one, 2019, Volume: 14, Issue:4

    Topics: Adult; Alopecia Areata; Case-Control Studies; DNA, Bacterial; Dysbiosis; Female; Humans; Male; Micro

2019
The profile of cytokines (IL-2, IFN-γ, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata.
    Journal of cosmetic dermatology, 2020, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cytok

2020
Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy.
    Experimental dermatology, 2020, Volume: 29, Issue:3

    Topics: Alopecia Areata; Autophagy; Autophagy-Related Proteins; Cysteine Endopeptidases; DNA Copy Number Var

2020
The effect of platelet rich plasma on hair regrowth in patients with alopecia areata totalis: A clinical pilot study.
    Dermatologic therapy, 2019, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Alopecia Areata; Female; Hair; Humans; Male; Pilot Projects; Platelet-Rich Plasma

2019
Method for describing patterns and distributions of alopecia areata which may be helpful for patient characterization and predicting prognosis.
    The Journal of dermatology, 2019, Volume: 46, Issue:8

    Topics: Administration, Topical; Adolescent; Alopecia Areata; Child; Cryotherapy; Female; Follow-Up Studies;

2019
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.
    Journal of cosmetic dermatology, 2019, Volume: 18, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Child; Combined Modality Therapy; Female;

2019
Nanoparticle Targeting to Scalp Hair Follicles: New Perspectives for a Topical Therapy for Alopecia Areata.
    The Journal of investigative dermatology, 2020, Volume: 140, Issue:1

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Alopecia Areata; Drug Delivery Systems; Hai

2020
Trichoscopy of alopecia areata in children. A retrospective comparative analysis of 50 children and 50 adults.
    Pediatric dermatology, 2019, Volume: 36, Issue:5

    Topics: Adult; Age Factors; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Hair Follicle; Hum

2019
Combination of tacalcitol ointment and photodynamic therapy for the treatment of follicular mucinosis of the scalp.
    Photodiagnosis and photodynamic therapy, 2019, Volume: 27

    Topics: Alopecia Areata; Aminolevulinic Acid; Dermatologic Agents; Dihydroxycholecalciferols; Drug Therapy,

2019
Dupilumab and alopecia: A Janus effect.
    Dermatologic therapy, 2019, Volume: 32, Issue:5

    Topics: Adult; Alopecia Areata; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Humans;

2019
Granulomatous alopecia: a variant of alopecia areata?
    Journal of cutaneous pathology, 2013, Volume: 40, Issue:4

    Topics: Adult; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Female; Glucocor

2013
Clinical and histopathological features of itch in patients with alopecia areata.
    Acta dermato-venereologica, 2013, Sep-04, Volume: 93, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Arachidonate 5-Lipoxygenase; Biopsy; Ca

2013
Prominent follicular mucinosis with diffuse scalp alopecia resembling alopecia areata.
    Journal of cutaneous pathology, 2013, Volume: 40, Issue:10

    Topics: Alopecia Areata; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Humans; Middle Aged; Muc

2013
Trichoscopy in paediatric patients with tinea capitis: a useful method to differentiate from alopecia areata.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2014, Volume: 28, Issue:9

    Topics: Alopecia Areata; Child; Child, Preschool; Dermoscopy; Diagnosis, Differential; Female; Hair; Humans;

2014
Vitiligo and alopecia areata: apples and oranges?
    Experimental dermatology, 2013, Volume: 22, Issue:12

    Topics: Adult; Alopecia Areata; Autoimmune Diseases; Dermatology; Humans; Inflammation; Male; Melanocytes; S

2013
Sudden onset hair loss and colour change.
    BMJ (Clinical research ed.), 2013, Oct-31, Volume: 347

    Topics: Acute Disease; Alopecia Areata; Biopsy; Diagnosis, Differential; Hair Color; Hair Follicle; Humans;

2013
Congenital temporal triangular alopecia: a typical Brauer nevus.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2013, Volume: 22, Issue:4

    Topics: Alopecia Areata; Child; Dermoscopy; Follow-Up Studies; Humans; Male; Monitoring, Physiologic; Nevus;

2013
Graves' disease associated with alopecia areata developing after Hashimoto's thyroiditis.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2013, Volume: 80, Issue:6

    Topics: Adult; Alopecia Areata; Female; Graves Disease; Hashimoto Disease; Humans; Scalp; Ultrasonography

2013
Patches of hair loss on the occipital scalp.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2014, Volume: 12, Issue:10

    Topics: Adolescent; Alopecia Areata; Atrophy; Biopsy; Dermoscopy; Hair Follicle; Humans; Intensive Care Unit

2014
Scalp conditions.
    Archives of disease in childhood. Education and practice edition, 2015, Volume: 100, Issue:1

    Topics: Alopecia Areata; Antifungal Agents; Child; Child, Preschool; Female; Glucocorticoids; Griseofulvin;

2015
Detailed clinicopathological characterization of progressive alopecia areata patients treated with i.v. corticosteroid pulse therapy toward optimization of inclusion criteria.
    The Journal of dermatology, 2014, Volume: 41, Issue:11

    Topics: Adolescent; Adult; Alopecia Areata; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middl

2014
Colocalization of vitiligo and alopecia areata presenting as poliosis.
    Journal of cutaneous pathology, 2015, Volume: 42, Issue:2

    Topics: Alopecia Areata; Child; Diagnosis, Differential; Humans; Male; Scalp; Vitiligo

2015
An observational study of alopecia areata in Sri Lankan adult patients.
    The Ceylon medical journal, 2014, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Age of Onset; Alopecia Areata; Autoimmune Diseases; Female; Humans; Male; Middle

2014
Hair dye: a trichoscopy pitfall.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:4

    Topics: Alopecia Areata; Color; Dermoscopy; Diagnosis, Differential; Diagnostic Errors; Hair Dyes; Humans; S

2015
Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata.
    The Journal of dermatology, 2015, Volume: 42, Issue:10

    Topics: Adult; Alopecia Areata; Case-Control Studies; Female; Forkhead Transcription Factors; Humans; Lympho

2015
Assessment of tissue levels of dickkopf-1 in androgenetic alopecia and alopecia areata.
    Journal of cosmetic dermatology, 2016, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Case-Control Studies; Female; Humans; Intercellular Si

2016
Annular alopecia areata: a morphologically rare variant.
    BMJ case reports, 2015, Oct-09, Volume: 2015

    Topics: Adolescent; Alopecia Areata; Autoimmune Diseases; Humans; Male; Scalp

2015
Biomarkers of alopecia areata disease activity and response to corticosteroid treatment.
    Experimental dermatology, 2016, Volume: 25, Issue:4

    Topics: Adrenal Cortex Hormones; Alopecia Areata; Biomarkers; Biopsy; Cytokines; Female; Gene Expression Pro

2016
Alopecia Areata Progression Index, a Scoring System for Evaluating Overall Hair Loss Activity in Alopecia Areata Patients with Pigmented Hair: A Development and Reliability Assessment.
    Dermatology (Basel, Switzerland), 2016, Volume: 232, Issue:2

    Topics: Adolescent; Adult; Alopecia Areata; Child; Dermoscopy; Disease Progression; Female; Hair Color; Huma

2016
Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse.
    The British journal of dermatology, 2016, Volume: 175, Issue:3

    Topics: Alopecia Areata; Epithelium; Female; Hair Follicle; Healthy Volunteers; Humans; Interferon-gamma; Pi

2016
Follicular mucinosis with diffuse scalp alopecia treated with narrow-band UVB phototherapy: the role of trichoscopy in monitoring therapeutic outcomes.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2016, Volume: 151, Issue:2

    Topics: Alopecia Areata; Dermoscopy; Female; Humans; Middle Aged; Mucinosis, Follicular; Scalp; Treatment Ou

2016
Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment.
    Archives of dermatological research, 2016, Volume: 308, Issue:5

    Topics: Alopecia Areata; Biopsy; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Humans; Lichen Planu

2016
Investigation on the role of necroptosis in alopecia areata: A preliminary study.
    Journal of the American Academy of Dermatology, 2016, Volume: 75, Issue:2

    Topics: Adult; Alopecia Areata; Apoptosis; Autophagy; Female; Humans; Male; Necrosis; Receptor-Interacting P

2016
Trichoscopy as a useful method to differentiate tinea capitis from alopecia areata in children at Zagazig University Hospitals.
    International journal of dermatology, 2017, Volume: 56, Issue:1

    Topics: Alopecia Areata; Child; Child, Preschool; Dermoscopy; Diagnosis, Differential; Egypt; Female; Hair;

2017
Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years.
    The Journal of dermatology, 2017, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Child; Child, Preschool; Cryotherapy; F

2017
Dermal Titanium Dioxide Deposition Associated With Intralesional Triamcinolone Injection.
    The American Journal of dermatopathology, 2016, Volume: 38, Issue:12

    Topics: Administration, Cutaneous; Alopecia Areata; Biopsy; Drug Compounding; Glucocorticoids; Humans; Injec

2016
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians.
    International journal of dermatology, 2017, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Asian People; Child; Dermoscopy; Diagno

2017
Efficacy of superficial cryotherapy on the eyebrows of patients with alopecia universalis also treated with contact immunotherapy on the scalp: a prospective, split-face comparative study.
    International journal of dermatology, 2017, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Alopecia Areata; Child; Cryotherapy; Cyclopropanes; Eyebrows; Female; Hair; Human

2017
Direct Immunofluorescence studies of patients with alopecia areata in affected and clinically normal areas of scalp.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alopecia Areata; Biopsy; Complement C3; Female; Fluorescent Antibody

2009
Value of transverse section scalp biopsy in alopecia areata - a clinicopathological correlation.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2008, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Child; Child, Preschool; Cross-Sectional Studies; Female

2008
The alpha-melanocyte stimulating hormone-related tripeptide K(D)PT stimulates human hair follicle pigmentation in situ under proinflammatory conditions.
    The British journal of dermatology, 2009, Volume: 160, Issue:2

    Topics: Aged; Alopecia Areata; alpha-MSH; Female; Hair Color; Hair Follicle; Hormones; Humans; Interleukin-1

2009
Decreased heme oxygenase-1 expression in the scalp of patients with alopecia areata: the pathogenic role of heme oxygenase-1.
    Journal of dermatological science, 2009, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Child; Female; Gene Expression; Heme Oxygenase-1; Humans; Male;

2009
Treatment of alopecia areata with fractional photothermolysis laser.
    International journal of dermatology, 2010, Volume: 49, Issue:7

    Topics: Adult; Alopecia Areata; Hair; Humans; Low-Level Light Therapy; Male; Scalp

2010
Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Anticholesteremic Agents; Drug Therapy, Combination

2010
Type 1 interferon signature in the scalp lesions of alopecia areata.
    The British journal of dermatology, 2010, Volume: 163, Issue:1

    Topics: Alopecia Areata; Hair Follicle; Humans; Interferon Type I; Lichen Planus; Lupus Erythematosus, Disco

2010
Melanocortin receptor type 2 (MC2R, ACTH receptor) expression in patients with alopecia areata.
    Experimental dermatology, 2010, Volume: 19, Issue:11

    Topics: Adult; Alopecia Areata; Cell Membrane; Cytoplasm; Dermis; Epidermal Cells; Epidermis; Female; Hair F

2010
'Follicular Swiss cheese' pattern--another histopathologic clue to alopecia areata.
    Journal of cutaneous pathology, 2011, Volume: 38, Issue:2

    Topics: Alopecia Areata; Humans; Scalp

2011
Treatment of alopecia areata with 308-nm excimer lamp.
    The Journal of dermatology, 2010, Volume: 37, Issue:12

    Topics: Adult; Aged; Alopecia Areata; Erythema; Female; Hair; Humans; Lasers, Excimer; Low-Level Light Thera

2010
Letter: Cerebriform intradermal nevus presenting as secondary cutis verticis gyrata.
    Dermatology online journal, 2010, Dec-15, Volume: 16, Issue:12

    Topics: Alopecia Areata; Diagnosis, Differential; Head and Neck Neoplasms; Humans; Male; Melanosis; Middle A

2010
Reflectance confocal microscopy of the yellow dot pattern in alopecia areata.
    Archives of dermatology, 2011, Volume: 147, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Dermoscopy; Female; Hair Follicle; Humans; Male; Microsc

2011
JAAD Grand Rounds quiz. Fixed focal alopecia for 20 years.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:5

    Topics: Adult; Alopecia; Alopecia Areata; Diagnosis, Differential; Hair Follicle; Humans; Male; Scalp

2011
Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-γ-induced collapse of human hair follicle immune privilege.
    Experimental dermatology, 2012, Volume: 21, Issue:3

    Topics: Alopecia Areata; Calcitonin Gene-Related Peptide; Calcitonin Receptor-Like Protein; Hair Follicle; H

2012
Association between scalp psoriasis and alopecia areata.
    La Tunisie medicale, 2012, Volume: 90, Issue:4

    Topics: Adult; Alopecia Areata; Humans; Male; Psoriasis; Scalp

2012
'Black dots' seen under trichoscopy are not specific for alopecia areata.
    Clinical and experimental dermatology, 2012, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Humans; Male;

2012
Congenital combined melanocytic nevus of the scalp with associated alopecia areata.
    The American Journal of dermatopathology, 2013, Volume: 35, Issue:4

    Topics: Alopecia Areata; Biomarkers, Tumor; Biopsy; Head and Neck Neoplasms; Humans; Immunohistochemistry; M

2013
Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids.
    Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:2

    Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Alopecia Areata; Anti-Inf

2013
Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients.
    Acta dermato-venereologica, 2002, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Alopecia Areata; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Bio

2002
Panniculitis-like T-cell lymphoma clinically manifested as alopecia.
    The British journal of dermatology, 2002, Volume: 147, Issue:4

    Topics: Alopecia Areata; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphoma, T-Cell, Cutan

2002
[Postmenopausal frontal fibrosing alopecia. Report of 3 cases].
    Annales de pathologie, 2002, Volume: 22, Issue:4

    Topics: Aged; Alopecia Areata; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Discoid; Middle

2002
Borderline tuberculoid leprosy and alopecia areata involving scalp.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2002, Volume: 70, Issue:3

    Topics: Adult; Alopecia Areata; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy, Tuberculoid;

2002
Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship?
    The Journal of rheumatology, 2003, Volume: 30, Issue:1

    Topics: Adult; Alopecia Areata; Calcinosis; Epilepsy, Tonic-Clonic; Female; Humans; Occipital Lobe; Scalp; S

2003
Striae distensae-like lesions. A cause of scarring alopecia among children.
    Saudi medical journal, 2002, Volume: 23, Issue:12

    Topics: Alopecia Areata; Atrophy; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Female; Humans

2002
Computerized morphometry and three-dimensional image reconstruction in the evaluation of scalp biopsy from patients with non-cicatricial alopecias.
    The British journal of dermatology, 2003, Volume: 148, Issue:2

    Topics: Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Biopsy; Female; Hair Follicle; Humans; Image Pro

2003
Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response.
    Clinical immunology (Orlando, Fla.), 2003, Volume: 106, Issue:3

    Topics: Alopecia Areata; Animals; Cytokines; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Mic

2003
Localized scalp hair shedding caused by Pheidole ants and overwiew of similar case reports.
    Dermatology online journal, 2003, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Alopecia Areata; Animals; Ants; Ectoparasitic Infestations; Female; Humans; Male;

2003
Alopecia areata and other common scalp problems.
    The Journal of the Medical Society of New Jersey, 1958, Volume: 55, Issue:5

    Topics: Alopecia; Alopecia Areata; Disease; Humans; Hyaluronoglucosaminidase; Hydrocortisone; Scalp; Skin Di

1958
Noncicatrizing alopecias; with special reference to alopecia areata.
    California medicine, 1958, Volume: 89, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Dermatologic Agents; Female; Glucocortico

1958
[Data on vascular spasm in the pathogenesis of various cases of alopecia areata].
    Borgyogyaszati es venerologiaia szemle, 1961, Volume: 37

    Topics: Alopecia; Alopecia Areata; Cardiovascular System; Humans; Scalp; Spasm; Vascular Diseases

1961
Nerve network of the hair follicle in alopecia areata.
    Archives of dermatology, 1960, Volume: 82

    Topics: Alopecia; Alopecia Areata; Hair Follicle; Humans; Scalp

1960
[Circumscribed lichenification of the hair of the head with simultaneous reversible alopecia].
    Dermatologische Wochenschrift, 1960, Feb-20, Volume: 141

    Topics: Alopecia; Alopecia Areata; Disease; Hair; Head; Humans; Scalp; Skin Diseases

1960
[Lupus erythematosus of the scalp with characteristics of alopecia areata].
    Archivos argentinos de dermatologia, 1961, Volume: 11

    Topics: Alopecia; Alopecia Areata; Disease; Humans; Lupus Erythematosus, Systemic; Medical Records; Scalp; S

1961
[Apropos of a case of chronic trichophytosis of the scalp, of pseudo-pelada type, due to Trichophyton verrucosum].
    Dermatologica, 1962, Volume: 125

    Topics: Alopecia; Alopecia Areata; Humans; Scalp; Tinea; Tinea Capitis; Trichophyton

1962
FLUOCINOLONE ACETONIDE IN PROPYLENE GLYCOL.
    Archives of dermatology, 1963, Volume: 88

    Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Dermatitis; Dermatitis, Atopic; Dermatitis, Sebo

1963
[CIRCUMSCRIBED NONMYCOTIC ALOPECIA-LIKE DISEASES OF THE SCALP IN CHILDREN].
    La Medecine infantile, 1965, Volume: 72

    Topics: Alopecia; Alopecia Areata; Child; Classification; Humans; Scalp; Scalp Dermatoses

1965
[Hair loss].
    Praxis, 2003, Sep-03, Volume: 92, Issue:36

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Biopsy; Child; Clinical Tria

2003
Histopathologic features of alopecia areata: a new look.
    Archives of dermatology, 2003, Volume: 139, Issue:12

    Topics: Adult; Aged; Alopecia Areata; Biopsy; Computer Graphics; Female; Humans; Male; Middle Aged; Prospect

2003
Tinea capitis in a 17 year old soldier (residual infection?); alopecia areata associated with tinea capitis?
    A.M.A. archives of dermatology and syphilology, 1950, Volume: 62, Issue:5

    Topics: Alopecia; Alopecia Areata; Humans; Microsporum; Military Personnel; Scalp; Tinea; Tinea Capitis

1950
[Alopecia areata and occipital angioma: fortuitous association or predictive factor?].
    Annales de dermatologie et de venereologie, 2004, Volume: 131, Issue:2

    Topics: Alopecia Areata; Hemangioma; Humans; Scalp; Skin Neoplasms

2004
Histopathological pictures of the initial changes of the hair bulbs in alopecia areata.
    The American Journal of dermatopathology, 2004, Volume: 26, Issue:3

    Topics: Adolescent; Alopecia Areata; Biopsy; Hair Follicle; Humans; Male; Scalp

2004
Videodermatoscopy enhances diagnostic capability in some forms of hair loss.
    American journal of clinical dermatology, 2004, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Child; Child, Preschool; Female; Hair; Hair Follicle;

2004
Interleukin-2 receptor alpha-chain expression in patients with alopecia areata.
    Acta dermatovenerologica Croatica : ADC, 2004, Volume: 12, Issue:3

    Topics: Adult; Aged; Alopecia Areata; Female; Humans; Immunohistochemistry; Lymphocyte Activation; Male; Mid

2004
[Circumscribed alopecia following furunculosis].
    Dermatologische Wochenschrift, 1950, Volume: 122, Issue:27

    Topics: Alopecia; Alopecia Areata; Animals; Furunculosis; Humans; Scalp

1950
Alopecia areata universalis sparing nevus flammeus.
    Dermatology (Basel, Switzerland), 2005, Volume: 210, Issue:3

    Topics: Adult; Alopecia Areata; Diagnosis, Differential; Humans; Male; Mosaicism; Port-Wine Stain; Scalp

2005
[Excimer laser therapy of alopecia areata--side-by-side evaluation of a representative area].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2005, Volume: 3, Issue:7

    Topics: Adult; Alopecia Areata; Follow-Up Studies; Hair; Humans; Low-Level Light Therapy; Male; Prospective

2005
Acute alopecia totalis.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2006, Volume: 15, Issue:1

    Topics: Adult; Alopecia Areata; Female; Glucocorticoids; Hair; Humans; Male; Methylprednisolone; Pulse Thera

2006
Thorium X and skin cancer: still a problem in the 21st century.
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:1

    Topics: Alopecia Areata; Carcinoma, Basal Cell; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm

2007
Alopecia areata associated with basal cell carcinoma developing within a naevus sebaceus.
    The British journal of dermatology, 2006, Volume: 155, Issue:5

    Topics: Adult; Alopecia Areata; Carcinoma, Basal Cell; Hamartoma; Humans; Male; Scalp; Scalp Dermatoses; Ski

2006
Multifocal scalp hair loss.
    Dermatology online journal, 2006, May-30, Volume: 12, Issue:4

    Topics: Adult; Alopecia Areata; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Ca

2006
Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells.
    Biochemical and biophysical research communications, 2007, May-11, Volume: 356, Issue:3

    Topics: Alopecia Areata; Drug Resistance; Hair Follicle; Humans; Hydrogen Peroxide; Immunohistochemistry; Re

2007
Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone.
    Archives of dermatological research, 2007, Volume: 299, Issue:5-6

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; CD8-Positive T-Lymphocytes; Cell Movement; Cyclopropanes

2007
Dry dermoscopy in clinical treatment of alopecia areata.
    The Journal of dermatology, 2007, Volume: 34, Issue:9

    Topics: Adult; Alopecia Areata; Dermoscopy; Diagnosis, Differential; Female; Hair; Hair Follicle; Humans; Ma

2007
Hair loss in children in South-East Nigeria: common and uncommon cases.
    International journal of dermatology, 2007, Volume: 46 Suppl 1

    Topics: Adolescent; Age Distribution; Alopecia; Alopecia Areata; Child; Child, Preschool; Female; Humans; In

2007
A case of widespread non-pigmented hair regrowth in diffuse alopecia areata.
    The Australasian journal of dermatology, 2007, Volume: 48, Issue:4

    Topics: Alopecia Areata; Eyebrows; Female; Glucocorticoids; Hair; Hair Color; Humans; Middle Aged; Pigmentat

2007
Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack.
    The Journal of investigative dermatology, 2008, Volume: 128, Issue:5

    Topics: Adolescent; Adult; Alopecia Areata; CD4 Antigens; CD56 Antigen; CD8 Antigens; CD8-Positive T-Lymphoc

2008
The role of scalp dermoscopy in the diagnosis of alopecia areata incognita.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:1

    Topics: Adult; Alopecia Areata; Biopsy; Dermoscopy; Female; Humans; Male; Scalp

2008
Immunofluorescent studies of complement C3 in the hair follicles of normal scalp and of scalp affected by alopecia areata.
    Acta dermato-venereologica, 1980, Volume: 60, Issue:1

    Topics: Adult; Aged; Alopecia Areata; Complement C3; Female; Fluorescent Antibody Technique; Hair; Humans; I

1980
[Comparative morphometric study of the sebaceous and sweat glands in alopecia areata, chronic diffuse and seborrheic baldness].
    Vestnik dermatologii i venerologii, 1982, Issue:10

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Child; Chronic Disease; Dermatitis, Seborrheic

1982
Immunohistochemical and electron microscopic characterization of the cellular infiltrate in alopecia (areata, totalis, and universalis).
    The Journal of investigative dermatology, 1984, Volume: 83, Issue:1

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Antibodies, Monoclonal; Child; Child, Preschool; Femal

1984
T cell subpopulations in alopecia areata.
    Journal of the American Academy of Dermatology, 1984, Volume: 11, Issue:2 Pt 1

    Topics: Adult; Alopecia Areata; Antibodies, Monoclonal; Child; Female; Fluorescent Antibody Technique; Hair;

1984
Subcutaneous blood flow in alopecia areata.
    Clinical and experimental dermatology, 1984, Volume: 9, Issue:2

    Topics: Adult; Aged; Alopecia Areata; Female; Humans; Male; Middle Aged; Regional Blood Flow; Scalp

1984
[Clinical and electron microscopy study of alopecia areata].
    Vestnik dermatologii i venerologii, 1984, Issue:5

    Topics: Alopecia Areata; Biopsy; Hair; Humans; Microscopy, Electron; Scalp

1984
Immunopathological studies on alopecia areata.
    Archives of dermatological research, 1980, Volume: 269, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Autoantibodies; Endothelium; Epidermis; Female; Fluorescent Anti

1980
[Surgical treatment in some types of alopecia (author's transl)].
    Ceskoslovenska dermatologie, 1981, Volume: 56, Issue:3

    Topics: Adult; Alopecia; Alopecia Areata; Female; Humans; Male; Scalp

1981
[Alopecia].
    Therapeutische Umschau. Revue therapeutique, 1980, Volume: 37, Issue:7

    Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Lupus Erythematosus, Systemic; Male;

1980
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines.
    The British journal of dermatology, 1993, Volume: 129, Issue:3

    Topics: Alopecia Areata; Cell Adhesion Molecules; Cytokines; Granulocyte-Macrophage Colony-Stimulating Facto

1993
Alopecia universalis in a patient with psoriasis vulgaris.
    The Journal of dermatology, 1995, Volume: 22, Issue:8

    Topics: Alopecia Areata; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Humans; Male; Middle Aged; Psorias

1995
Abnormalities in the ultrastructure of melanocytes and the outer root sheath of clinically normal hair follicles from alopecia areata scalps.
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Alopecia Areata; Cytoplasmic Granules; Epidermis; Epithelium; Hair; Humans; Melanocytes; Scalp

1995
Immunity to hair follicles in alopecia areata.
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Alopecia Areata; Autoantibodies; Autoantigens; Autoimmune Diseases; Hair; Humans; Immunoglobulin G;

1995
T-cell receptor repertoire V beta in alopecia areata.
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Alopecia; Alopecia Areata; Case-Control Studies; Gene Expression; Genetic Variation; Hair; Humans; L

1995
Histopathology of alopecia areata in horizontal sections of scalp biopsies.
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Adolescent; Adult; Aged; Alopecia Areata; Biopsy; Child; Child, Preschool; Female; Hair; Humans; Inf

1995
Glucocorticoid regulation of hair growth in alopecia areata.
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Alopecia; Alopecia Areata; Calcium; Calmodulin; Case-Control Studies; Glucocorticoids; Hair; Humans;

1995
Is the dermal papilla a primary target in alopecia areata?
    The Journal of investigative dermatology, 1995, Volume: 104, Issue:5 Suppl

    Topics: Alopecia Areata; Autoantibodies; Autoimmune Diseases; Basement Membrane; CD4-Positive T-Lymphocytes;

1995
Clinical and histologic findings in temporal triangular alopecia.
    Journal of the American Academy of Dermatology, 1994, Volume: 31, Issue:2 Pt 1

    Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Hair; Humans;

1994
[Bilateral linear temporoparietal scleroderma en coup de sabre].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1994, Volume: 45, Issue:6

    Topics: Adult; Alopecia Areata; Autoantibodies; Collagen; Diagnosis, Differential; Female; Hair; Humans; Sca

1994
[Alopecia areata and diffuse hypotrichosis associated with Ullrich-Turner syndrome. Presentation of 4 patients].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1993, Volume: 44, Issue:10

    Topics: Adult; Alopecia Areata; Female; Hair; Humans; Hypotrichosis; Scalp; Turner Syndrome

1993
Pulse of methylprednisolone in alopecia areata.
    Dermatology (Basel, Switzerland), 1993, Volume: 187, Issue:4

    Topics: Adolescent; Adult; Alopecia Areata; Drug Administration Schedule; Drug Tolerance; Face; Female; Foll

1993
Pseudopelade of Brocq is lichen planopilaris: report of four cases that support this nosology.
    Cutis, 1993, Volume: 51, Issue:2

    Topics: Adult; Aged; Alopecia Areata; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermato

1993
Hairy pigmented congenital naevocellular naevus in a patient with alopecia universalis.
    Clinical and experimental dermatology, 1993, Volume: 18, Issue:2

    Topics: Adolescent; Alopecia Areata; Female; Humans; Nevus, Pigmented; Scalp; Skin Neoplasms

1993
Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone.
    Dermatology (Basel, Switzerland), 1995, Volume: 191, Issue:1

    Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Cyclopropanes; Follow-Up Studies; Hair;

1995
No correlation between cytomegalovirus and alopecia areata.
    The Journal of investigative dermatology, 1996, Volume: 107, Issue:3

    Topics: Adolescent; Adult; Alopecia Areata; Cytomegalovirus; DNA, Viral; Humans; In Situ Hybridization; Scal

1996
Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps.
    The British journal of dermatology, 1996, Volume: 135, Issue:2

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Hair Follicle; Humans; Microscopy, Electron; Middle Aged

1996
Differential T-cell reactivity to the round and oval forms of Pityrosporum in the skin of patients with psoriasis.
    The British journal of dermatology, 1997, Volume: 136, Issue:3

    Topics: Adult; Alopecia Areata; Autoantibodies; CD4-Positive T-Lymphocytes; Cell Line; Cell Wall; Cytoplasm;

1997
Possible involvement of neuropeptidergic sensory nerves in alopecia areata.
    Neuroreport, 1997, Mar-24, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Calcitonin Gene-Related Peptide; Case-Control Studies; H

1997
Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata.
    Journal of the American Academy of Dermatology, 1997, Volume: 37, Issue:1

    Topics: Alopecia Areata; Biopsy; Eosinophils; Hair; Hair Follicle; Humans; Scalp

1997
Nonscarring alopecia associated with solitary circumscribed neuroma.
    Dermatology (Basel, Switzerland), 1997, Volume: 195, Issue:3

    Topics: Aged; Alopecia Areata; Female; Humans; Neuroma; Scalp; Skin Neoplasms

1997
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice.
    The Journal of clinical investigation, 1998, Jan-01, Volume: 101, Issue:1

    Topics: Adult; Alopecia Areata; Animals; Autoimmune Diseases; Cells, Cultured; Female; HLA-DR Antigens; Huma

1998
[Temporary roentgen epilation after embolization of a cerebral arteriovenous malformation].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:4

    Topics: Adult; Alopecia Areata; Cerebral Angiography; Dose-Response Relationship, Radiation; Embolization, T

1998
Localised alopecia of the scalp. Common causes.
    Australian family physician, 1998, Volume: 27, Issue:10

    Topics: Adolescent; Alopecia; Alopecia Areata; Child; Humans; Infant, Newborn; Scalp; Tinea Capitis; Trichot

1998
Pronounced perifollicular lymphocytic infiltrates in alopecia areata are associated with poor treatment response to diphencyprone.
    European journal of dermatology : EJD, 1999, Volume: 9, Issue:2

    Topics: Administration, Topical; Alopecia Areata; Case-Control Studies; Cyclopropanes; Hair Follicle; Humans

1999
Diagnosis: alopecia areata or not?
    Seminars in cutaneous medicine and surgery, 1999, Volume: 18, Issue:1

    Topics: Adolescent; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Humans; Middle Aged; Scalp

1999
Nurse's cap alopecia.
    International journal of dermatology, 1999, Volume: 38, Issue:3

    Topics: Adult; Alopecia Areata; Female; Hair Follicle; Humans; Korea; Microscopy, Electron; Middle Aged; Nur

1999
Temporary hair loss simulating alopecia areata after endovascular surgery of cerebral arteriovenous malformations: a report of 3 cases.
    Archives of dermatology, 1999, Volume: 135, Issue:12

    Topics: Adult; Alopecia Areata; Diagnosis, Differential; Embolization, Therapeutic; Female; Humans; Intracra

1999
Role of cytotoxic T cells in chronic alopecia areata.
    The Journal of investigative dermatology, 2000, Volume: 114, Issue:1

    Topics: Alopecia Areata; Antigens, CD; Chronic Disease; Cytokines; HLA-DR Antigens; Humans; Immunohistochemi

2000
Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I.
    Biochemical and biophysical research communications, 2000, Jan-07, Volume: 267, Issue:1

    Topics: Alopecia Areata; Autoantibodies; Autoantigens; Europe; Gene Library; Humans; Isoenzymes; Polyendocri

2000
Characterization of infiltrating T cells in human scalp explants from alopecia areata to SCID nude mice: possible role of the disappearance of CD8+ T lymphocytes in the process of hair regrowth.
    The Journal of dermatology, 1999, Volume: 26, Issue:12

    Topics: Adult; Alopecia Areata; Animals; CD4-CD8 Ratio; Female; Hair; HLA-DR Antigens; Humans; Immunohistoch

1999
Migratory poliosis: A forme fruste of alopecia areata?
    Journal of the American Academy of Dermatology, 2000, Volume: 42, Issue:6

    Topics: Adult; Alopecia Areata; Black People; Cell Movement; Hair Color; Humans; Male; Scalp

2000
Expression of neuropeptide-degrading enzymes in alopecia areata: an immunohistochemical study.
    The British journal of dermatology, 2001, Volume: 144, Issue:1

    Topics: Adult; Alopecia Areata; E-Selectin; Endothelium, Vascular; Female; Hair Follicle; Humans; Immunoenzy

2001
Functional analysis of the stratum corneum of scalp skin: studies in patients with alopecia areata and androgenetic alopecia.
    Archives of dermatological research, 2000, Volume: 292, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Cheek; Child; Female; Forearm

2000
Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice.
    The Journal of investigative dermatology, 2001, Volume: 117, Issue:6

    Topics: Adult; Alopecia Areata; Animals; Autoantigens; Cell Extracts; Epitopes, T-Lymphocyte; Female; Hair F

2001
Antioxidant enzymes and lipid peroxidation in the scalp of patients with alopecia areata.
    Journal of dermatological science, 2002, Volume: 29, Issue:2

    Topics: Adult; Alopecia Areata; Glutathione Peroxidase; Humans; Lipid Peroxides; Male; Scalp; Superoxide Dis

2002
Dinitrochlorobenzene therapy for alopecia areata.
    Archives of dermatology, 1978, Volume: 114, Issue:11

    Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Dinitrochlorobenzene; Drug Eruptions; Female; Human

1978
[Deposits of complement C3 in the hair follicle of normal scalp and alopecia areata (author's transl)].
    Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1979, Volume: 89, Issue:7

    Topics: Adult; Aged; Alopecia Areata; Complement C3; Female; Hair; Humans; Male; Scalp

1979
[Aplasia cutis circumscripta congenita].
    Wiener medizinische Wochenschrift (1946), 1977, Jun-20, Volume: 127, Issue:12

    Topics: Acute Disease; Alopecia Areata; Dermatologic Surgical Procedures; Diagnosis, Differential; Female; H

1977
[Immunohistological study of alopecia areata (author's transl)].
    Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1979, Volume: 89, Issue:14

    Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Female; Fluorescent Antibody Technique;

1979
Alopecia areata: immunofluorescence and other studies.
    The British journal of dermatology, 1978, Volume: 99, Issue:4

    Topics: Adolescent; Adult; Alopecia Areata; Autoantibodies; Child; Female; Humans; Immunoglobulins; Male; Mi

1978
Diagnosing the common alopecias.
    American family physician, 1978, Volume: 18, Issue:5

    Topics: Alopecia; Alopecia Areata; Biopsy; Humans; Lupus Erythematosus, Discoid; Scalp; Tinea Capitis; Trich

1978
[The histodynamic of alopecia areata in the dependence on the griseofulvin-induced epithelial proliferation (author's transl)].
    Archives of dermatological research, 1978, Dec-01, Volume: 263, Issue:3

    Topics: Alopecia Areata; Cell Division; Epithelium; Griseofulvin; Hair; Humans; Scalp

1978
Cellular activity in the dermis surrounding the hair bulb in alopecia areata.
    Journal of cutaneous pathology, 1975, Volume: 2, Issue:5

    Topics: Alopecia Areata; Connective Tissue; Connective Tissue Cells; DNA; Epithelial Cells; Epithelium; Fema

1975
Alopecia areata.
    Journal of cutaneous pathology, 1975, Volume: 2, Issue:5

    Topics: Alopecia Areata; Female; Humans; Middle Aged; Scalp

1975
Follicular mucinosis in alopecia areata.
    The American Journal of dermatopathology, 1992, Volume: 14, Issue:6

    Topics: Adolescent; Alopecia Areata; Female; Humans; Immunohistochemistry; Mucinosis, Follicular; Scalp; T-L

1992
The transverse anatomy of androgenic alopecia.
    The Journal of dermatologic surgery and oncology, 1990, Volume: 16, Issue:12

    Topics: Alopecia Areata; Frozen Sections; Hair; Humans; Male; Scalp; Staining and Labeling

1990
Expression of tenascin in perifollicular connective tissue: comparison of normal scalp and alopecia areata.
    Archives of dermatological research, 1991, Volume: 283, Issue:2

    Topics: Alopecia Areata; Cell Adhesion Molecules, Neuronal; Connective Tissue; Extracellular Matrix Proteins

1991
The ultrastructure of the dermal papilla-epithelial junction in normal and alopecia areata hair follicles.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Alopecia Areata; Biopsy; Epithelium; Hair; Humans; Intercellular Junctions; Reference Values; Scalp

1991
Evidence for a subclinical state of alopecia areata.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Alopecia Areata; Biopsy; Female; Hair; Humans; Male; Reference Values; Scalp

1991
Transient defects in cortical cell differentiation form the exclamation-mark shaft in acute alopecia areata.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Acute Disease; Adult; Alopecia Areata; Cell Differentiation; Hair; Humans; Microscopy, Electron; Mic

1991
Three distinct patterns of cell degeneration in acute alopecia areata.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Acute Disease; Alopecia Areata; Cell Death; Hair; Humans; Keratinocytes; Microscopy, Electron; Necro

1991
Cryosectioning of hair follicles. An improved method using liquid nitrogen conduction freezing.
    Acta dermato-venereologica, 1990, Volume: 70, Issue:4

    Topics: Alopecia Areata; Biopsy; Freezing; Hair; Hair Diseases; Humans; Immunohistochemistry; Nitrogen; Scal

1990
[Asymptomatic increase in the telogen rate].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1991, Volume: 42, Issue:3

    Topics: Adult; Alopecia Areata; Diagnosis, Differential; Female; Hair Diseases; Humans; Scalp

1991
[Temporal arteritis with scalp and tongue necrosis and brain stem infarct].
    Medizinische Klinik (Munich, Germany : 1983), 1990, Volume: 85 Suppl 1

    Topics: Aged; Alopecia Areata; Brain Stem; Cerebral Infarction; Diagnosis, Differential; Female; Giant Cell

1990
Haemorheological parameters in alopecia areata.
    Folia haematologica (Leipzig, Germany : 1928), 1985, Volume: 112, Issue:6

    Topics: Adolescent; Adult; Alopecia Areata; Blood Viscosity; Child; Erythrocyte Deformability; Female; Human

1985
Increase of mast cells in the alopecia lesion of mice.
    Acta dermato-venereologica, 1985, Volume: 65, Issue:1

    Topics: Alopecia Areata; Animals; Cell Count; Hair; Humans; Mast Cells; Mice; Mice, Inbred Strains; Scalp; S

1985
Alopecia areata incognita: a hypothesis.
    Dermatologica, 1987, Volume: 174, Issue:5

    Topics: Alopecia Areata; Androgens; Dermatitis, Seborrheic; Hair; Humans; Scalp; Stochastic Processes

1987
In situ lymphocyte subsets in alopecia areata before and during treatment with a contact allergen.
    Clinical and experimental dermatology, 1987, Volume: 12, Issue:4

    Topics: Adult; Aged; Alopecia Areata; Dinitrochlorobenzene; Female; Humans; Lymphocytes; Male; Middle Aged;

1987
Corroborative evidence that alopecia areata involves the epidermis and the sebaceous glands.
    The American Journal of dermatopathology, 1987, Volume: 9, Issue:2

    Topics: Adult; Alopecia Areata; Autoradiography; Epidermis; Female; Hair; Humans; Male; Scalp; Sebaceous Gla

1987
Quantification of scalp hair--a computer-aided methodology.
    The Journal of investigative dermatology, 1986, Volume: 86, Issue:1

    Topics: Alopecia Areata; Analog-Digital Conversion; Hair; Humans; Photography; Scalp; Statistics as Topic

1986
Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice.
    Archives of dermatology, 1987, Volume: 123, Issue:1

    Topics: Alopecia; Alopecia Areata; Animals; Cyclosporins; Female; Graft Survival; Hair; Humans; Male; Mice;

1987
Hair loss. Common congenital and acquired causes.
    Postgraduate medicine, 1986, Volume: 79, Issue:5

    Topics: Adolescent; Alopecia; Alopecia Areata; Androgens; Child; Diagnosis, Differential; Female; Hair; Huma

1986
[Aplasia cutis congenita and foetus papyraceus].
    Orvosi hetilap, 1985, Mar-31, Volume: 126, Issue:13

    Topics: Adult; Alopecia Areata; Female; Fetal Diseases; Humans; Infant, Newborn; Placenta; Placenta Diseases

1985
Epidemic alopecia areata. An outbreak in an industrial setting.
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1971, Volume: 13, Issue:11

    Topics: Adult; Alopecia Areata; Biopsy; Breast; Canada; Dermatitis, Occupational; Disease Outbreaks; Environ

1971
Cutaneous corticosteroid injection and amaurosis. Analysis for cause and prevention.
    Archives of dermatology, 1974, Volume: 110, Issue:5

    Topics: Alopecia Areata; Blindness; Blood Pressure; Embolism; Eye; Female; Humans; Hydrocortisone; Injection

1974
[Determination of vascular flow in peladic patches with xenon 133].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1972, Volume: 79, Issue:2

    Topics: Alopecia Areata; Hemodynamics; Humans; Methods; Radioisotopes; Regional Blood Flow; Scalp; Skin; Xen

1972
Regrowth of hair in nevus flammeus.
    Archives of dermatology, 1972, Volume: 105, Issue:5

    Topics: Alopecia Areata; Female; Hair; Hemangioma; Humans; Middle Aged; Regional Blood Flow; Scalp

1972
[Basal cell carcinomas of the hairy head simulating "alopecia areata"].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1972, Volume: 23, Issue:4

    Topics: Adult; Alopecia Areata; Carcinoma, Basal Cell; Diagnosis, Differential; Female; Humans; Male; Middle

1972
Tonsure trichotillomania.
    The British journal of dermatology, 1970, Volume: 82, Issue:4

    Topics: Adolescent; Adult; Alopecia Areata; Depression; Diagnosis, Differential; Female; Hair; Humans; Middl

1970
Can scalp hair suddenly turn white? A case of canities subita.
    Archives of dermatology, 1970, Volume: 102, Issue:1

    Topics: Alopecia Areata; Hair; Humans; Male; Middle Aged; Pigmentation; Scalp

1970
[Are there any connections between sensory innervation of the head and location of the alopecia areata foci?].
    Dermatologische Monatschrift, 1970, Volume: 156, Issue:7

    Topics: Alopecia Areata; Autonomic Nervous System; Humans; Peripheral Nerves; Scalp; Time Factors

1970
[Chronic diffuse lupus erythematosus of the head with enormous horny protuberances and decalvant pelada].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1967, Volume: 74, Issue:1

    Topics: Alopecia Areata; Face; Head; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Scalp

1967
The blood vessels of the scalp in patients with alopecia areata before and after corticosteroid therapy.
    The British journal of dermatology, 1968, Volume: 80, Issue:11

    Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Alopecia; Alopecia Areata; Biopsy; Hair; Humans; Hydr

1968
[Study of the apparently normal scalp in alopecia areata].
    Medicina espanola, 1965, Volume: 53, Issue:313

    Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Scal

1965
[Hair root pattern in psoriasis vulgaris of the scalp].
    Archiv fur klinische und experimentelle Dermatologie, 1966, May-27, Volume: 225, Issue:1

    Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Female; Hair; Hair Removal; Human

1966